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內容摘要 
B 組鏈球菌 ( 6 ’此 ;想•如 ‘ e )或稱 G r o u p B S t r e p t o c o c c u s (GBS)是一種革蘭 
氏染色陽性的兼性球菌，主要分佈在人體的生殖道和胃腸道中。在1887年首 
次從患有乳腺炎的牛身上發現，但直至六十年代才被介定為人類的致病原。從 
發現至今，本菌已被識別出九種血清型(serotypes) ( l a � l b � I I � I I I � I V � V � 







血清型分型(molecular s e r o t y p e s ) �脈衝式電泳指紋 ( P d s e d - f i e l d ge l e l e c t r o p h o r e s i s 
f ingerpr ints)> 攜帶的表面蛋白質基因(surface p r o t e i n g e n e s ) �抗藥性基因 ( a n t i b i o t i c 
r e s i s t a n c e genes)和一系列與致病有關的插入序列(insertion s e q u e n c e ) �血清型 I I I 
G B S 是最常見的血？青型(35.4%),其次是 l a ( 1 5 . 1 % ) , V ( 1 4 . 3 % ) , I I (12.7%)，lb 
( 9 . 7 % ) , V I ( 3 . 8 % ) , V I I ( 1 . 1 % ) , V I I I ( 1 . 1 % )及 V ( 0 . 8 % ) 0 另有 5.9%的菌株為不能分 
類 ( n o n - t y p e a b l e ) � 8 9 . 5 %的G B S對四園素有抵抗性，並且大多數攜帶基 
因。23.8% (88/370)的菌株對紅黴素有抵抗性，最常出現是e/772(B)基因（43菌株)， 
其次是和 _ T R )基因。導致侵襲性疾病的 G B S主要為血清型 I I I中的 
• I I 
三個子型(subtype),他們主要從細菌囊的基因和可移動的遺傳因數(mobile 










Streptococcus agalactiae or Group B streptococcus (GBS) is a facultative anaerobic 
gram-positive coccus that colonizes the human genital and gastrointestinal tracts. 
GBS was first discovered in 1887 as a pathogen in bovine mastitis and was only 
regarded as a human pathogen in the 1960s. Nine serotypes (la, lb, II，III, IV, V，VI， 
VII and VIII) have since been identified. Among these, la, II，III and V were the 
most prevalent in causing diseases in the USA and Western Europe. GBS is the 
major pathogen in neonatal diseases and also causes diseases in adults. 
Three hundred and seventy non-duplicate GBS isolates selected between 1993 -
2003 April from the Prince of Wales Hospital, Hong Kong were examined. One 
hundred and ninety four isolates were isolated from blood, cerebrospinal fluid and 
pus specimens, and one hundred and seventy six isolates were collected from 
vaginal/rectal swabs of pregnant mothers or swabs from neonates. These were swabs 
taken from colonizaing sites of GBS included ear, eye and umbilical cord. These 
• isolates were typed by agglutination test, and the antibiotic susceptibilities were 
determined by microbroth dilution method. They were further characterized by 
molecular methods to determine their molecular serotypes, pulsed-field gel 
electrophoresis fingerprints, and the presence of surface protein genes, antibiotic 
resistance determinants and insertion sequences associated with virulence 
determinants by polymerase chain reaction. Serotype III was the commonest serotype 
(35.4%), the other serotypes were la (15.1%), V (14.3%), II (12.7%), lb (9.7%), VI 
(3.8%), VII (1.1%), VIII (1.1%) and IV (0.8%). 5.9% of isolates were non-typeable. 
89.5% GBS were resistant to tetracycline and the majority harboured tet{^) gene. 
IV 
23.8% (88/370) isolates were resistant to erythromycin. Erm(B) gene was the most 
prevalent (43 isolates), followed by me/{A) and erm{TR) genes. GBS causing 
invasive disease clustered into 3 major subtypes of serotype III by a combination of 
capsular gene sequences, the presence/absence of mobile genetic elements, IS1548 
and GBSil : MS III subtypes III-l (cluster III-A) and III-2 (cluster III-B) were 
predominant in neonatal invasive diseases. Whilst, subtype III-4 (cluster III-C) was 
identified to cause invasive disease in adult and particular associated with a unique 
cluster of invasive disease in healthy non-pregnant adult in Hong Kong in 1998. GBS 
strains in cluster V-B were characterized by non-haemolytic colonies on blood agar. 
A real-time PGR assay was developed to detect GBS and differentiate MS III 
subtypes III-l and III-2 from other serotypes. The assay has been shown to be 
sensitive and specific to GBS, although more extensive study is needed to evaluate 
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Chapter 1 Introduction 
Chapter 1 Introduction 
1.1 Taxonomy oi Streptococcus agalactiae 
Streptococcus agalactiae is a member of the Genus Streptococcus. It is 
phylogenetically classified in the Order Lactobacillales and in the Family of 
Streptococcaceae (http://www.ncbi.nlm.nih.gov/taxonomy). Streptococci were 
differentiated by haemolytic reaction on blood agar，sugar fermentation and tolerance 
tests. Streptococcus agalactiae was originally discovered in cattle with mastitis and 
is now known to be a human pathogen. In the 1930s, beta-haemolytic streptococci 
were serologically classified by Lancefield and the carbohydrate antigen on the 
capsular surface of Streptococcus agalactiae was assigned as B antigen (Paoletti et 
ai, 2000), thus the bacterium was also named Group B streptococcus or in short 
GBS. 
1.2 Characteristics oi Streptococcus agalactiae 
Streptococcus agalactiae (GBS) is a gram positive coccus that grows in chains. It is 
. facultatively anaerobic, catalase negative and oxidase negative. It is common in the 
normal flora in the human genital and gastrointestinal tracts. In vitro, it grows 
optimally at 37°C supplemented with 5% CO2 and shows a narrow p-haemolytic 
zone around the colony on blood agar. It is distinguished from other streptococci by a 
positive CAMP factor test, hydrolysis of hippurate and arginine, the prescence of 
alkaline phosphatase and production of acetoin. It ferments ribose and trehalose 
(Kilian, 1998). 
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The antigen that classifies Streptococcus agalactiae to Lancefield group B is group B 
carbohydrate present on capsular surface and is unique to GBS. All serotypes of GBS 
express group B carbohydrate on their capsular surfaces (Facklam, 2002), which is 
composed of rhamose, galactose, N-acetylglucosamine and glucitol. These sugars 
build different oligosaccharide units that are linked by phosphodiester bonds. The 
linkages create a complicated and highly branched tetra-antennary structure. GBS 
can be subdivided into 9 serotypes, la, lb, II-VIIL The serotypes are differentiated 
by expressing type specific antigen on the capsule. The antigens are constructed by a 
repeating unit consisting four of the following five sugars, glucose, galactose, N-
actylglucosamine, rhamnose and sialic acid (Paoletti et al, 2000). However, a 
number of GBS isolates may not be categorized into serotypes and are classified as 
non-typeable. This condition is not rare and may be due to inactivation of capsular 
polysaccharide synthesis by gene insertions (Cieslewicz et al., 2001; Sellin et al.’ 
2000)，reversible encapsulation phase variation (Sellin et al, 1995), decreased 
capsular expression in colonizing isolates or expression of uncharacterized 
polysaccharide (Palacios et al., 1997; Slotved et al., 2002). Methods that reduce the 
.. number of non-typeable strains have been proposed (Benson et al., 2002). 
A variety of identification methods has been developed for GBS. Biochemical 
methods detect the production of certain enzymes and fermentation reactions. 
Commercial kits like API 20 Strep and ID 32 Strep, (BioMerieux, France) are 
available for presumptive identification. However, the available biochemical tests are 
not able to differentiate GBS serotypes. 
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Immunological methods have been used for rapid identification of GBS. Commercial 
latex agglutination kits such as Streptex (Murex, UK), Prolex-Blue (Pro-Lab 
Diagnostics, UK), Streptococcus Grouping Kit (Oxoid, UK) etc. by targeting the B 
antigen on GBS (Davies et al,’ 2003). A latex method has also been developed for 
serotyping GBS (Slotved et al, 2003). This provided a convenient method for large 
scale serotyping. 
Various molecular methods have been developed for identification of GBS by 
conventional or real-time PCR (Ahmet et al.’ 1999; Bergh et al.’ 2004; Ke et al, 
2000; Kong et al, 2002b) and by DNA probe hybridization (Borchardt et al.’ 2004). 
1.3 Epidemiology of GBS 
1.3.1 Risk groups 
GBS affects the extremes of age, the pregnant and those with underlying diseases. 
1.3.1.1 Neonates 
. GBS neonatal infection can be divided into two categories, early-onset and late-onset 
diseases. Early-onset disease refers to disease occurring within the first week of life. 
Most of the cases are evident on the day of birth or even through the first hour of life. 
Late-onset disease occurs at the time between 1 week and 3 months of life. The 
clinical syndromes caused by GBS include sepsis, meningitis, pneumonia and less 
often osteomyelitis and septic arthritis. Although the clinical presentations of early-
onset and late-onset disease are overlapping, there is some variation, such as 24% of 
late onset diseases presents as meningitis but only 6% in early-onset diseases. The 
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risk of long-term neurologic sequelae are also more likely higher among survivors of 
late-onset diseases (Gibbs et al, 2004). The risk factors that correlate to early-onset 
disease have been well describe (Adair et al, 2003; Manning, 2003; Oddie et al, 
2002) and included maternal age, GBS colonization, number of weeks of gestation, 
prolonged rupture of membranes and preterm delivery. Most of these risk factors 
correspond to the maternal condition during pregnancy and at delivery (Adair et al, 
2003; Campbell et al., 2000; Oddie et al., 2002; Schuchat，1998). However, the risk 
factors of late-onset diseases are not well understood. There is little correlation with 
maternal complications during labor. Prematurity of the neonate is likely a major risk 
factor and perhaps, the source of GBS for late-onset disease is also considered as a 
risk factor (Lin et al.’ 2003; Schuchat, 1998). 
The majority of early-onset diseases is acquired from the mother who is colonized by 
GBS. It has been proven that the pulsed-field gel electrophoresis patterns of the GBS 
isolates from both mother and neonate pairs were indistinguishable (Hansen et al., 
2004). Neonates may have been infected by the ascending spread of GBS in the 
amniotic fluid across intact amniotic membrane or aspiration of infected vaginal 
. fluids during birth (Gotoff, 2002; Schrag et al., 2002; Schuchat, 1998). With late-
onset diseases, possible transmission routes include breast milk (Dinger et al, 2002; 
Kotiw et al, 2003), and nosocomial acquisition (Hickman et al., 1999; Lin et al.’ 
2003; Schuchat, 1998). It may also reflect a delayed manifestation after early 
colonization (Dinger et al.，2002), 
Since the introduction of antepartal prophylaxis in 1996 in the United States, the 
incidence of early-onset diseases has decreased by 70% to 0.5 cases per 1000 live 
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births (Schrag et al.’ 2002), and was further reduced to 0.31 cases per 1000 live 
births by 2003 (http://www.cdc.gov/ncidod/dbmd/abcs). In contrast, the incidence of 
late-onset diseases has remained relatively constant at 0.31 cases per 1000 live births 
(http://www.cdc.gov/ncidod/dbmd/abcs). Now, late-onset diseases are as common as 
or more common than early-onset disease in United States (Gibbs et al, 2004). 
1.3.1.2 Pregnant women 
GBS is a part of the normal flora in the vaginal and gastrointestinal tract. GBS can 
either colonize asymptomatic ally or cause non-invasive or invasive disease. The 
clinical presentation can vary from mild urinary tract infection to life-threatening 
sepsis including amnionitis, endometritis, cellulitis, meningitis and endocarditis 
(Schuchat, 1998)； 
Maternal GBS colonization is also a threat to the fetus. GBS colonization has been 
associated with preterm labor, preterm premature rupture of amniotic membrane and 
stillbirth (Gibbs et al., 2004; Schuchat, 1998). GBS colonization is also a major risk 
factor for early-onset disease of neonates. 
The colonization rate of pregnant mother varies from 10% to 40% (Gotoff, 2002; 
Schrag et al, 2002; Whitney et al, 2004). However, these values may not represent 
the true rate of GBS colonization in pregnancy. Geographic, ethnic and 
socioeconomic factors may influence the carriage rates. Colonization may be chronic, 
intermittent or transient (Schrag et al, 2002), and may be caused by fluctuations of 
bacterial flora proportions during pregnancy and/or sensitivity of the detection 
methods. Intermittent GBS carriage has been shown and the same clone of GBS has 
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been isolated after two or more subsequent negative cultures during the sampling 
period. This may have been due to the low sensitivity of culturing techniques, non-
optimal transportation time, and temperature of storage (Stoner et al, 2004). 
Therefore, the actual colonization rates may be higher than those currently reported 
(Hansen et al., 2004). 
1.3.1.3 Non-pregnant adult 
Increasing trend of invasive GBS infection has been described around the world 
(Blancas et al.’ 2004; Blumberg et al.’ 1996; Schuchat, 1998; Wilder-Smith et al, 
2000). The incidence has been reported to have risen 2 to 4 fold in the last decade 
(Farley, 2001). In 2002 CDC reported that the incidence and mortality rate of GBS 
disease increased with patient's age from 0.5 cases per 100,000 populations to 23.8 
cases per 100,000 populations with exceptionally high incidences (71.9 cases per 
100,000 populations) in those aged below 1 year 
(http://www.cdc.gov/ncidod/dbmd/abcs). Individuals who were 65 years or older and 
living in nursing homes were more susceptible to GBS infection (Henning et al, 
2001). GBS causes various diseases including osteomyelitis, arthritis, pneumonia, 
bacteriemia, meningitis and endocarditis (Farley, 2001). Underlying diseases 
increase the risk for GBS disease and some predisposing conditions that are highly 
correlated to GBS infection include diabetes mellitus, previous stroke, decubitus 
ulcer, cirrhosis, breast cancer and neurogenic bladder. As many elderly persons have 
one or more underlying diseases, this may explain the higher incidence rate among 
them (Henning et al, 2001; Jackson et al.，1995). 
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The transmission of adult GBS infection includes by the fecal-oral route and sexual 
transmission (Bliss et al, 2002; Manning et al.’ 2002). However, factors that lead to 
the transition of asymptomatic carriage to infection are unclear (Manning, 2003). 
1.3.2 World wide distribution 
1.3.2.1 Serotypes 
The predominant serotypes of GBS diseases in the last decade were la, lb, II and III. 
However, serotype V has emerged and reduced the proportion of the other serotypes 
among colonization and disease strains. Serotype III is still predominant among most 
risk groups (Harrison et al., 1998). 
The increase in serotype V prevalence was not accounted for by the production of 
serotype V antiserum, because non-typeable strains were previously reported in only 
a small percentage of cases (Harrison et al., 1998). Moreover, serotype V isolates 
with indistinguishable pulsed-field gel electrophoresis fingerprints have been seen 
are the same period, and from different countries in the last decade (Thomas-Bories 
et al., 2001). It is thus believed that pathogenic serotype V has emerged as a recent 
event. 
Serotypes VI，VII and VIII and their capsular polysaccharide structures were 
discovered in the 1990s (Kogan et al, 1995; Kogan et al., 1996; von Hunolstein et 
al, 1993). These three serotypes were seldom reported. However, recent reports have 
shown the presence of serotype VIII in Japan, Korea, Portugal and Denmark 
(Ekelund et al, 2003; Figueira-Coelho et al, 2004; Lachenauer et al,’ 1999; Lee et 
al，2000) and those reported from Japan and Denmark were particularly involved in 
• 22 
Chapter 1 Introduction 
invasive diseases (Ekelund et al., 2003; Hoshina et al., 2002). Antisera to serotypes 
VI，VII and VIII were not always available in serotyping, and those serotypes may 
thus have been categorized non-typeable strains. Table 1.1 shows the serotype 
distribution world wide. 
1.3.2.2 Antibiotic susceptibility 
Penicillin remains the first line drug for treatment. Penicillin tolerance or lower 
susceptibility is only rarely reported (Betriu et al., 1994; Bland et al, 2001; de 
Azavedo et al., 2001; Hsueh et al, 2001). However, increasing resistance to 
erythromycin and clindamycin in GBS have been reported from various countries 
(Betriu et al., 2003; Figueira-Coelho et al.’ 2004; Schrag et al, 2002)，with 
prevalence of erythromycin resistance from 3% to 46% (Betriu et al, 2003; Hsueh et 
al, 2001; Lee et al, 2000; Lopardo et al.’ 2003; Matsubara et al., 2001; Wemo et al, 
2003). The prevalence of tetracycline resistance in GBS vary from 26% to 100% in 
different countries, but in most were higher than 80%. The lowest resistance rate was 
found in Japan, while a 100% prevalence was found in Korea (Duarte et al., 2005; 
Ko et al, 2001; Lee et al., 2000; Matsubara et al., 2001; Poyart et al.’ 2003; Wemo 



















































































































































































































































































































































































































































































































































































































































Chapter 1 Introduction 
1.3.3 GBS diseases in Hong Kong 
A suspected GBS outbreak in Hong Kong in 1998 has also been described (Wilder-
Smith et al，2000). In previous studies from Hong Kong the incident of early-onset 
disease was 0.58 cases per 1000 live births and the maternal colonization rate was 
19% in the 1980s (Chan et al, 1986; Liang et al, 1986). Sporadic reports of neonatal 
stridor, adult necrotizing fasciitis, toxic shock syndrome and bacteriemia caused by 
GBS have been reported (Abdullah et al., 2002; Tang et al, 2000; Wang et al.’ 2002; 
Wilder-Smith et al.’ 2000). Data relating to the epidemiology of GBS are lacking and 
there is little description of the serotype distribution and characteristic of GBS 
diseases in the population, 
1.4 Putative virulence factors and pathogenesis 
Generally, the pathogenesis of bacterial infection involves three major processes; the 
adherence to cell surfaces, penetration of host cellular barriers and avoidance of 
immunologic clearance (Nizet et al, 2000). GBS adheres to epithelial surfaces to 
compete with other microflora for a niche on various mucosal surfaces. Invasion and 
injury to cells and tissues are processes for nutrient hunting, and may activate the 
host immune system (Doran et al.’ 2004; Herbert et al., 2004). Extensive putative 
factors that may facilitate each process had been described (Nizet et al., 2000). 
1.4.1 Capsular polysaccharide 
GBS are encapsulated and the capsular polysaccharide has been known as a 
virulence determinant for a long time. Isogenic capsule-deficient mutants have 
shown increased immune clearance by rats (Nizet et al.’ 2000). The highly branched 
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polysaccharide was able to hide the surface protein from antibody and phagocytosis 
(Herbert et al., 2004). The capsule also protected GBS from complement-mediated 
lysis (Areschoug et al, 2002). 
All GBS capsules have a terminal a2->3-linked sialic acid to mimic the surface of 
mammalian cells, which can decrease immune recognition (Doran et al, 2004). 
Inhibition of C3 deposition on the capsular surface also protected GBS from 
opsonophagocytosis (Wessels et al, 1995) and activation of the complement cascade. 
1.4.2 C5a peptidase 
C5a peptidase is a protease expressed in virtually all GBS (Cheng et al, 2002a). The 
protein is encoded by the ScpB gene. The ScpB gene consist of 3450 base pair and 
the product protein is approximately 120kDa (Chmouryguina et al.’ 1996). C5a 
peptidase inactivates C5a by hydrolyzing at His-67 in the neutrophil binding site, and 
thus delays the recruitment of phagocytes to the infection site (Bohnsack et al, 1997). 
It also enhances survival of GBS by reducing phagocyte killing. 
‘ Recent findings also show that C5a peptidase has a function to mediate adherence of 
GBS to fibrdnectin, and thus may facilitate the persistence and colonization by GBS 
on epithelial surfaces (Beckmann et al., 2002). Moreover, invasion of GBS to lung 
epithelial cell in vitro was inhibited by anti-C5a peptidase serum, indicating the 
involvement of C5a peptidase in invasion (Cheng et al., 2002b). 
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1.4.3 p-haemolysin/cytolysin 
Beta-haemolysin/cytolysin is a membrane bound protein controlled by the cylE gene 
(Pritzlaff et al, 2001) and its expression contributes to the characteristic feature of a 
narrow beta-haemolytic zone around the colony. The P-haemolysin has been 
demonstrated to potentiate GBS sepsis in an animal model (Ring et al., 2002a), and 
cause injury to lung epithelial and endothelial cells (Gibson et al, 1999; Nizet et al., 
1996). It is characterized as a pore-forming cytolysin forming pores in cell 
membrane (Nizet et al.’ 2000), and promoting GBS invasion into human lung 
epithelial cells (Doran et al, 2002). 
Beta-haemolysin/cytolysin has been shown to induce apoptosis of immune cells 
(Fettucciari et al, 2000) and to trigger inducible nitric oxide production. This may 
induce proinflammatory properties relevant in the sepsis cascade (Ring et al., 2002b). 
It has been found to be an inflammation activator and mediator of release of 
interleukins ip, 6 and 8 (Doran et al, 2002; Nizet, 2002). 
1.4.4 C protein and C a-like protein 
1.4.4.1 C protein 
C protein is a surface expressed complex protein on GBS. C protein consists of two 
distinct components, a and (3. The a component is also called C a protein, which is 
trypsin resistant. Similarly, the P component is also named C P protein, but it is 
‘ trypsin sensitive. The a and p components are independently expressed as different 
products, and they possibly relate to enhanced virulence and resistance to 
opsonophagocytosis (Chun et al, 1991; Michel et al, 1991; Nizet et al, 2000). 
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1.4.4.1.1 C a protein 
The C a protein is of variable size and is expressed in GBS by the bca gene. The 
gene consists of a signal sequence, N-terminal region, a series of tandem repeat units, 
a partial repeat region and a C-terminal region. The tandem repeat unit consists of 82 
amino acids which are encoded by 246 nucleotides. Variations in the number of 
repeat units have been observed, but the sequences within each unit are highly 
conserved (Michel et al, 1992). 
The C a protein is commonly expressed in GBS serotype la, lb and II (Bolduc et al., 
2002). It has been suggested to be involved in resistance to opsonophagocytosis and 
cellular invasion (Bolduc et al, 2002; Maeland et al, 2000). The repeating unit in 
bca is responsible for the escape from immune clearance. The originally identified C 
a protein was a nine tandem repeat with size of 140kDa (Michel et al., 1992). 
However there is variation in protein size in clinical isolates, which correspond to the 
number of repeat units present in bca gene. The distribution of repeat unit numbers 
varied from 4 to 16 in clinical isolates (Gravekamp et al., 1996; Gravekamp et al, 
• 1998;Madoffe^ a l , 1991). 
The variation in repeat unit numbers can alter the immunological epitopes of the C a 
protein. Experiments have shown that antibody elicited to larger repeat C a proteins 
has lower binding affinity to fewer repeats protein, but antibody elicited from fewer 
repeat proteins bind both larger and smaller proteins with equal affinity. This 
indicates that variation in this region critically alters the antigenic structure and as the 
immunological epitopes (Gravekamp et al, 1996). 
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Since the repeat unit number in clinical isolates is apparently normally distributed, it 
may imply there is natural selection for increased as well as decreased repeat unit 
numbers. A decrease in repeat number has been observed to enhance pathogenicity in 
immune neonatal mice. On the other hand, an increase in repeat unit number may be 
required for optimal interaction with eukaryotic cells (Bolduc et al., 2002; 
Gravekamp et al., 1998). 
1.4.4.1.2 C P protein 
The C p protein is the p subunit of C protein. It is encoded by the bac gene in GBS, 
and the gene consists of a signal sequence, N-terminus, two functional domains (A 
and B), a repetitive genetic element near the C-terminus, a cell wall-spanning and a 
cell membrane-spanning C-terminal domain. Insertion, deletion or both have been 
observed in the repetitive genetic element, these contribute to the polymorphism of C 
P protein (Bemer et al., 2002; Maeland et al, 1999). 
C p protein is suspected to be a virulence factor because of its IgA binding ability. C 
• p protein is able to bind to IgA via its Fc portion. Because secretory IgA on mucosal 
surface is the first line of defense against pathogenic micro-organism, binding of IgA 
by surface protein may block deposition of IgG and complement on bacterial surface. 
The binding probably masks other surface antigens and inhibits phagocytosis. In 
addition, streptococcal IgA-binding protein can inhibit binding of IgA to human IgA 
‘ receptor CD89, an mediator of IgA effector function. This may interfere subsequent 
process normally triggered by binding the IgA Fc portion to CD89. These include 
phagocytosis, superoxide generation, release of inflammatory mediators, and as 
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contribute to bacterial virulence (Bemer et al, 2002; Nagano et ai, 2002; Pleass et 
a/.，2001). 
From a recent study, researchers found C P protein had a binding site for human 
factor H, a complement regulator of the alternative pathway. Factor H can act as a 
cofactor to facilitate degradation of C3b complement component with factor I. 
Because the bacteria-bound factor H retains its ability, it is possible to down-regulate 
complement activation. GBS may use the bound factor H to evade complement 
attachment (Areschoug et al.’ 2002). 
1.4.4.2 C a-like protein 
C a protein and C a-like protein belong to a family of proteins with unique repetitive 
structure which shows characteristics of immunological cross-reactivity, large 
internal tandem repeat region, extremely similar N- and C-terminal encoding region 
and a regular ladder-like pattern on immunoblot (Lachenauer et al, 2000; Wastfelt et 
al, 1996). The C a-like protein candidate includes Rib protein, R protein and Alp2 
and Alp3 proteins (Lachenauer et al., 1996; Lachenauer et al, 2000; Stalhammar-
• Carlemalm et al., 1993). 
Within the macrostructure of this protein family, there are variations in nucleotide 
sequences of repeating domain or combination of domains with different predicted 
functions. For example, Alp2 protein consists of tandem repeats similar to Rib 
protein, but it has an IgA binding domain similar to C (3 protein and a additional 
repeat at the C-terminus that is apparently derived from C a protein. The variety of C 
a-like proteins was suggested to be produced by mosaic formation following 
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horizontal gene transfer of partial or whole genes and subsequent incorporated by 
recombination (Lachenauer et al, 2000). 
The distribution of surface proteins and serotypes was concordant, however, a 
specific PGR showed genes of C a, rib, alp2 and alp3 proteins to be seldom 
simultaneously found in single isolates. This may reflect clonal lineages within a 
species (Kong et al, 2002a; Lachenauer et al, 2000). 
1.4.5 Hyaluronate lyase 
Hyaluronate lyase is a 111 kDa surface exposed protein expressed by the hylB gene 
in the GBS genome. The enzyme has been incorrectly assigned as a neuraminidase in 
the past (Pritchard et al., 1993). Hyaluronate lyase was suspected as a virulence 
factor following to the observation that strains producing high level of the enzyme 
were frequently found to be the most virulent strains (Lin et al, 1994). 
The major target of hyaluronate lyase is hyaluronan. It is a major matrix substance in 
elastin and collagen. Hyaluronan is widely distributed in cartilage, nervous tissue and 
. soft connective tissue. The lyase may also play a role in immunological modulation. 
In the mouse, it can stimulate activated alveolar macrophages to express mRNAs of 
numerous chemokines and cytokines (Turino et al, 2003). The activation may be 
through the hyaluronan receptor CD44 expressed on the macrophage surface (Lin et 
al, 1994). Hyaluronate lyase also has ability to degrade chondroitin sulphate, which 
‘ is also a component of cartilages (Baker et al.，1997). 
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As the hyaluronan and chrondroitin sulphate play a role in matrix formation, 
hyaluronate lyase from GBS is suggested to facilitate spread and invasion of tissue. 
Moreover, it possibly interferes with the function of immune cells (Lin et al, 1994; 
Turino et al., 2003). 
1.4.6 CAMP factor 
CAMP factor is a 23.5kDa extracellular protein. CAMP reaction refers to synergistic 
haemolytic reaction produced by colonies of GBS streaked adjacent to colonies of 
Staphylococcus aureus on blood agar (Liu et al., 2004). 
CAMP factor was known as a pathogenic determinant because of its lethal effect 
when administered to rabbits and mice. It is a pore forming toxin that forms large 
oligomeric pores up to 12 - 15mm in diameter on susceptible membranes (Lang et 
al., 2003)，CAMP factor also weakly binds to the Fc portion of IgG and IgM and 
provides immunological protection from opsonophagocytosis (Jurgens et al., 1987). 
1.4.7 Others 
Numerous less well known or newly found factors including lipoteichoic acid, 
fibronectin, surface-anchored protein Spbl, penicillin-binding protein, carbohydrate 
toxin CMlOl and different oligopeptidases, an being investigated for their role in the 
virulence of GBS. Their present role in virulence and mechanisms of action are 
unclear (Doran et al., 2004; Herbert et al., 2004; Liu et al, 2004). 
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1.5 Antibiotic resistance and resistance genes 
1.5.1 Macrolides 
The products of macrolide resistance genes can be divided into methylase, efflux 
proteins or enzymes for inactivation (Nakajima, 1999). £r/n(B), erw(TR) and mef[A) 
are more frequently detected in GBS and explain most of the resistance (Betriu et al, 
2003; de Azavedo et al., 2001; Hsueh et al, 2001). Erm{B) and erm{TR) encode 
methylases which modify 23 S rRNA and results in resistance to erythromycin and 
other macrolides. Because 23 S rRNA is also the target of lincosamides and 
streptogramin B, the presence of a methylase gene results in cross resistance and the 
macrolide, lincosamide and streptogramin B phenotype (MLSB) (Fluit et al.’ 2001). 
Expression of M L S B resistance can be constitutively expressed or inducible. 
Inducible M L S B phenotype is expressed only after induction by exposure to a low 
concentration of a member of M L S B antibiotics e.g. erythromycin (Roberts et al.’ 
1999; Rosato et al., 1999). MeJ{A) encodes a efflux protein and confers resistance to 
macrolides only, therefore, resistance by meJ{A) is named Macrolide (M) phenotype. 
In addition to resistance genes which confer macrolides resistance genes, point 
mutations in 23S rRNA can result in erythromycin resistance (Fitoussi et al, 2001; 
Nakajima, 1999). 
1.5.2 Tetracyclines 
, At least 24 tetracycline resistance genes have been identified (Fluit et ai, 2001). 
Their gene products can be divided into ribosomal protection proteins, efflux 
proteins and enzymes that inactivate tetracyclines. Six determinants have been 
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detected among streptococci, including ^er(K), tet{L), teti}A), tet{0), tet{Q) and tet{T) 
(Chopra et al, 2001). encodes protein molecules that protect the ribosome 
and is the most frequent determinant in GBS isolates (Culebras et al, 2002; Duarte et 
al., 2005; Poyart et al, 2003). Tet(}A) was frequently found in conjugative 
transposons of the LN916 family including LN916 and TYU545 and is widespread 
among gram positive cocci (Clewell et al., 1995; Rice, 1998). In addition, an 
erythromycin resistance gene and a kanamycin resistance gene have been 
simultaneously carried by Tnl545 (Caillaud et al” 1987; De et al, 2004; Rice, 1998). 
Acquistion of these transposons may cause resistance to tetracycline, erythromycin 
and kanamycin. Therefore, detection of the integrase gene {int-Tn) of the ln916 
family may explain the route of acquisition of these resistance genes (Montanari et 
al., 2003; Poyart et al.’ 2003). 
1.5.3 Aminoglycosides 
The mechanism for aminoglycoside resistance can be divided into reduced 
intracellular concentration, target modification and enzymatic drug modification. 
Drug modification is the major cause of aminoglycoside resistance (Magnet et al.’ 
* 2005). Numerous aminoglycoside modifying enzymes have been found and these 
have been divided into aminoglycoside adenylyltransferases (also named 
aminoglycoside nucleotidetransferases, ANTs), aminoglycoside phosphotransferases 
(APHs) and aminoglycoside acetyltransferases (AACs) (Fluit et al, 2001; Magnet et 
al, 2005). 
The aminoglycoside resistance gene aphAS encodes 3'5'-aminoglycoside 
phosphotransferase type III，and is able to inactivate kanamycin by transferring 
19 
Chapter 1 Introduction 
phosphate (Mahillon et al., 1997; Smith et al, 2002; Trieu-Cuot et al., 1983). High 
level kanamycin resistance in group A streptococci has been reported to be due to 
this enzyme (van Asselt et al, 1992) and it is present on transposon lnl545 which 
also harboured tetracycline and erythromycin resistance genes (Caillaud et al, 1987; 
Rice, 1998). 
Another resistance gene, aad6, encodes an aminoglycoside 6-adenylyltranserase 
(Schwarz et al., 2001), which transfers the adenyl group to streptomycin conferring 
streptomycin resistance (Magnet et al., 2005; Smith et al, 2002). 
1.5.4 Fluoroquniolones 
Fluoroquniolone antibiotics target DNA gyrase and topoisomerase IV to inhibit DNA 
replication. These two enzymes are heterotetrameric proteins and are composed of 
two subunits encoded by gyrk and gyrB, parC and parE respectively. Mutation at 
the quinolone resistance-determining region in one of these four genes can impart 
resistance to fluoroquinolones (Fluit et al.’ 2001), If mutation occurs at the gene of 
the two enzymes simultaneously, it confers high level resistance to fluoroquinolones 
*� (Hooper, 2002). High level resistance to fluoroquinolone has been reported in GBS, 
and the resistance is conferred by point mutations in both gyrA and parC (Kawamura 
et al., 2003). 
1.5.5 Others 
Chloramphenicol resistance is mainly caused by chloramphenicol acetyltransferase 
(cat) genes. The cat gene is classified into two types, A and B. The cat gene 
identified in GBS belongs to type A subgroup A-7 with similar amino acid sequence 
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to the catC gene (Schwarz et al.’ 2004). Lincosamide resistance is mainly expressed 
by the gene giving the M L S B phenotype. However, lincosamide specific 
nucleotidyltransferase genes linA\ link and /mB (Roberts et al, 1999) and the efflux 
pump ImrK gene (Weisblum, 2000) have also been reported to result in lincosamide 
resistance. 
1.6 Mobile genetic elements 
A mobile genetic element is a genetic entity capable of independent inter-molecular 
and intra-molecular movement. The mobile genetic element allows for genomic 
rearrangements (Mahillon, 1998) and is important in generating genetic variability 
and diversity through insertion, alternating gene expression and generating DNA 
rearrangement (Nagy et al., 2004). The mobile genetic elements are classified by 
general structure and functional organization including size, conserved DNA regions 
and number of open reading frame (Mahillon, 1998). 
Several insertion sequences have been extensively studied in GBS including IS 1548， 
IS861，IS1381，lSSa4, ISSagl, ISSag2 (Franken et al,’ 2001; Franken et al, 2004; 
Granlund et al.’ 1998; Rubens et al, 1989; Spellerberg et al” 2000; Tamura et al, 
2000) and group II intron GBSil (Luan et al.’ 2003). An insertion sequence is a 
small, genetically compact element that only encodes for mobility (Mahillon et al, 
1998). While a group II intron is a large catalytic RNA molecule that acts as a mobile 
genetic element (Martinez-Abarca et al., 2000), their exact functions in GBS are 
unclear. The distribution of these mobile genetic elements have been studied and 
suggested to be useful markers for the classification of GBS strains. ISSagl and 
lSSag2 possibly relate to genetic transfer (Franken et al,, 2001; Franken et al, 2004). 
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1875^5 and GBSil had been discovered and are distributed among serotype III 
isolates (Granlund et al., 2001), and suggested to be associated with serotype III 
meningitis isolates (Bidet et al.’ 2003)，whilst IS1548 had been described to be found 
predominantly in serotype III isolates that cause endocarditis (Granlund et al., 1998). 
IS567 has been found in several serotypes, and was able to differentiate bovine GBS 
when coupled with IS1548 (Dmitriev et al., 2003)，IS1381 was commonly found in 
GBS and had been used for GBS subtyping (Tamura et al., 2000), lSSa4 was 
discovered only in serotype II isolates and may represent a specific lineage of 
serotype II strains (Dmitriev et al.’ 2004). 
1.7 Typing methods 
The hypothesis for typing of micro-organism is based on the fact that clonally related 
isolates will share characteristic by which they can be differentiated from unrelated 
isolates. In general, an outbreak of infection is caused by a pathogen derived from a 
single cell whose progeny are genetically identical or closely related to the source 
organism. Therefore, typing systems employ the differences in characteristics to 
determine the source of infection and recognize particularly virulent strains (Arbeit, 
1999; Olive et al., 1999). 
A variety of typing methods have been used for GBS. They are categorized into 
phenotypic and genotypic methods. These methods can be characterized in terms of 
typeability, reproducibility, discriminatory power, ease of performance and ease of 
interpretation (Tenover et al, 1997). A comparison of the commonly used methods is 
summarized in Table 1.2. 
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1.7.1 Phenotypic methods 
Phenotypic methods are based on the products of gene expression for differentiating 
strains. The products of gene expression have the tendency to vary when the 
organism were subjected to change in growth conditions, growth phase and 
spontaneous mutation. Therefore, strains that are genetically indistinguishable may 
vary in the phenotype detected (Arbeit, 1999; Tenover et al, 1997). 
1.7.1.1 Sero typing 
Serotyping has been the classical way of characterizing GBS. This method relies on 
the specific antigenic determinants expressed on the cell surface of GBS. However, 
there are several limitations as the discriminatory power is low and serotyping 
mainly groups isolates into a few large categories. It is less sensitive to differentiate 
important difference among epidemiological unrelated strains and has relatively high 
frequency of non-typeable isolates (Arbeit, 1999). GBS has been characterized into 9 
serotypes la, lb, II-VIII. Since the serotype distribution has been found to be similar 
between healthy carrier and patients, serotyping may not be sufficient to differentiate 
colonizing and pathogenic GBS strains (Lammler et al., 1995). A major limitation is 
the costs of the specific reagents for typing (Manning, 2003). 
1.7.1.2 Multilocus enzyme electrophoresis (MLEE) 
Multilocus enzyme electrophoresis is a protein based method and analyses the 
variation in protein mobility in starch gel electrophoresis. The mobility change of 
protein is due to amino acid substitution of the gene which causes in a change of the 
charge of the corresponding protein and thus mobility. It has good reproducibility 
and typeability, but its limitations include low discriminatory power for 
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epidemiologically related and unrelated strains and technical demanding (Manning, 
2003). It has previously been used successfully to differentiate a virulent subtype of 
GBS serotype III (Musser et al, 1989). 
1.7.2 Genotypic methods 
Genotypic methods analyse the bacterial genetic structure, often through the 
polymorphism in DNA restriction patterns. Examples included pulsed-field gel 
electrophoresis (PFGE) (Bidet et al, 2003; von Both et al, 2003), restriction 
endonuclease analysis (REA) (Nagano et al, 1991), random amplified polymorphic 
DNA (RAPD) (Chatellier et al, 1997; Limansky et al, 1998)，real-time PCR, and 
sequencing (Jones et al, 2003; Ke et al., 2000; Kong et al.’ 2002b). 
1.7.2.1 Restriction endonuclease analysis (REA) / restriction 
fragment-length polymorphism (RFLP) 
Restriction endonuclease analysis (REA) employs the specific cleavage property of 
restriction endonucleases. Total DNA is cleaved by restriction endonuclease with 
restriction sites in the genome. The digested DNA is then resolved by linear gel 
electrophoresis and the generated restriction profile will have variable band sizes, 
vary from 0.5 to 50 kilo basepair (bp), thus providing a unique restriction profile for 
a particular strain (Tenover et al, 1997). Similar fingerprints are assigned to the 
same profile of restriction digestion patterns (RDPs). The REA method has been 
applied to subtype GBS, and HindlW digestion has allowed identification of a RDP 
III-3 group from invasive GBS isolates (Nagano et al, 1991; Takahashi et al., 1998). 
However, the most significant limitation of REA is the difficulty to interpret complex 
restriction profiles (Manning, 2003). 
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Restriction fragment-length polymorphism (RFLP) is a method modified from REA, 
with the addition of southern blotting. Resolved digested DNA on a nylon membrane 
is hybridized with a chemically or radioactively labeled specific probe, so limiting 
the number of fragments of the fingerprint. The major drawback is the difficulty of 
performing the test (Manning, 2003; Tenover et al, 1997). 
1.7.2.2 Pulsed-field gel electrophoresis (PFGE) 
Pulsed-field gel electrophoresis was first described in 1984 for examining 
chromosomal DNA of eukaryotic organisms. It is a method that uses a rare-cutting 
enzyme to digest chromosomal DNA to generate approximately 10 to 30 fragments 
that are resolved on pulsed-field electrophoresis. It produces fewer fragments then 
REA and thus easier to interpret. It is reproducible and often with high 
discriminatory power, it is a widely used for typing gram-negative and gram positive 
bacteria including GBS (Manning, 2003; Tenover et al., 1997). Moreover, guidelines 
for interpretation of PFGE result has been proposed and widely used (Tenover et al, 
1995). For GBS typing, rapid PFGE methods have been developed and the 
,� significantly reduce the length of the method from 5 days to 3 days without altering 
the discriminatory power (Benson et al., 2001). 
Although PFGE is a powerful tool for molecular typing, the limitations are the 
expensive equipment, and the laborious and a relatively time consuming 
, methodology (Manning, 2003; Olive et ai, 1999). 
25 
Chapter 1 Introduction 
1.7.2.3 Random amplified polymorphic DNA (RAPD) 
RAPD, also named arbitrary primer PCR, uses short random sequence primers (9 -
10 bp) for amplification. The primers hybridize to chromosomal DNA at low 
annealing temperature. If two primers are hybridized in the correct orientations and 
within few kilo basepair distance, PCR products of corresponding sizes are generated. 
The location and number of primer sites vary between bacterial strains, thus the band 
pattern can represent particular strain (Olive et al, 1999). Although the RAPD 
discriminatory result is able to correlate to MLEE for invasive isolates, its 
reproducibility greatly limits the usage in typing (Chatellier et al., 1997). 
1.7.2.4 Sequencing 
DNA sequencing has the highest reproducibility, discriminatory power, and 
typeability. Because all molecular methods are based on difference in DNA 
sequences, logically, sequencing gives the ultimate fingerprint for an organism. The 
major hindrance for using DNA sequencing for typing is the cost (Olive et al., 1999). 
Sequencing typing for GBS has been developed to categorize GBS isolates into 9 
•� serotypes and also enabled further subtyping molecular serotype III into 4 subtypes 
(Kong et al.’ 2002b). 
Another approach employing DNA sequencing is multilocus sequencing typing 
(MLST). MLST is a sequence-based typing method, it involves sequencing 
‘ approximately 500 bp fragment of seven housekeeping genes. The sequence of each 
gene is assigned to an allelic number, the combination of the allelic number of the 
seven genes contribution to a unique profile. The profile is convenient for 
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epidemiological studies because data can be compared between database or 
laboratories over the internet (Davies et al, 2004a). MLST has been applied in GBS 
and has shown a clonal relationship within serotype III (Davies et al, 2004a). The 
phylogenetic relationship between different clones could also be predicted by 
computation (Feil et al.’ 2004). 
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Table 1.2 Characteristics of strain typing methods 
Typing Typeability Reproducibility Discriminatory Ease of Ease of 
system power interpretation Performance 
Serotyping Most Good Fair Moderate Moderate 
MLEE All Excellent "^od “ Excellent Good 
REA — All Good Good Difficult —Moderate 
RFLP 一 All Excellent Moderate “ Moderate 一 Difficult 
PFGE M Excellent Excellent Moderate Moderate 
RAPD “ All Fair Good Fair Good 
Sequencing All Excellent Excellent Excellent Fair 
(Olive et al.’ 1999; Tenover et al.’ 1997) 
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1.8 Prevention 
1.8.1 Intrapartum antibiotic prophylaxis (lAP) 
GBS is the leading pathogen affecting neonates. Vertical transmission is the major 
transmission route of GBS between colonized mothers and neonates (Gotoff, 2002). 
In order to reduce neonatal GBS diseases, guidelines for prevention was introduced 
in the USA during the 1990s by the American College of Obstetricians and 
Gynecologists (ACOG), Center for Disease Control and Prevention (CDC) and 
American Academy of Pediatrics (AAP) (AMERICAN ACADEMY OF 
PEDIATRICS, 1997; Centers for Disease Control and Prevention, 1996). 
With implementation of intrapartum prophylaxis in the CDC guidelines, early-onset 
disease incidence in neonates has been reported to have declined in the USA (Centers 
for Disease Control and Prevention, 2004) and France (Dumas et al.’ 2004). The 
major approach of the CDC guidelines was to identify by screening for GBS 
colonization or by risk groups of the pregnant mothers and provide intrapartum 
prophylaxis to these mothers whose neonates would be at risk of GBS infection. A 
summary of the guidance from CDC (Centers for Disease Control and Prevention, 
1996; Schrag et al., 2002) is illustrated in Figure 1.1 and Figure 1.2. 
Generally, the antimicrobial agent used in intrapartum prophylaxis are penicillin or 
ampicillin. Penicillin is the preferred choice because of its narrower spectrum for 
selection of resistance organism. For penicillin allergic women, cefazolin, 
erythromycin, clindamycin and vancomycin are the altemativse (Alarcon et al.’ 2004; 
Schrag et al, 2002). 
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Although lAP is effective in reducing early-onset disease, there are concerns over 
anaphylactic reactions with the use of antibiotics, the possibility for emergence of 
GBS or non-GBS antibiotic resistant strains, and increase of neonatal infection 
caused by non-GBS pathogens (Moore et al, 2003; Schrag et al, 2002). So far, there 
is no emergence of resistant GBS. Trends in E, coli, the second leading pathogen in 
neonatal disease, are stable or in decline in various studies (Alarcon et al, 2004; 
Daley et al,, 2004; Rentz et al., 2004) except in the group of preterm, low birth 
weight and very low birth weight neonates in which neonatal sepsis caused by 
ampicillin resistant E. coli has increased (Alarcon et al, 2004; Moore et al., 2003). 
Continuous evaluation of the effectiveness of lAP, antibiotic resistance among GBS 
and other flora, and bacterial colonization of mothers and infants are critical to 
reduce the possible risks that may be brought by lAP (Alarcon et al., 2004; Moore et 
a/., 2003). 
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Vaginal and rectal GBS screening cultures at 36-37 weeks* gestation for ALL pregnant women {iffiiess patient had GBS bacteriuria 
during the currant pregnancy or a previous infant with invasive GBS disease) 
‘ 1 ‘ 1 • 
Intrapartum prophylaxis Indicated Intrapartum prophylaxis not Indicated 
• Prevtous Intanl with Invasive GBS disease • Previous pregnancy wtm a positive GBS 
screening culture (unless a culture was also 
• GBS bacteriuria during current pregnancy positive during the current pregnancy) 
• Positive GBS screening culture during current pregnancy • Planned cesarean deltvery pertormed in the 
(unless a planned cesarean delivery, in the absence of fabor absertc^ of tabor or membrane rupture 
or amniotic membrane rupture, Is performed) (regardtosd of maternal GBS culture status) 
» Unknown GBS status (culture not done, incomplete^ • Negative vaginal and rectal GBS screening 
or results unknown) and any of the loliovving: culture in late gestation during the current 
• Delivery at <37 weeks，gMon^ ^ 二 哪 ‘ r e g a r d l e s s of intrapartum r»sK 
• Amniotic membrane rupture >18 hours 
• Intrapartum temporaturo 之 100,4〒 ^38.0^0)* 
，if onset of labor or rupture of amniotic membranes occurs at <37 weeks' gestation and there is a s i^ f icanl risk for preterm delivery (as assossed by 
.the dinioian), a suggested algorittvn for GBS prophylaxis management is provided (Figure 3)< 
If armionitis is suspected, broad-spectrum antibiotic therapy that indudes an agent known to be active against GBS should replace GBS prophytaxis. 
Figure 1.1 Criteria for intrapartum prophylaxis by screening 
(Schrag et al, 2002) 
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Are any of the following risk factors present? 
Previously delivered infant 
who had invasive GBS disease 
GBS bacteriuria during this pregnancy Yes Give 
„ . , … ^ intrapartum 
Delivery at <37 weeks gestation* penicillin卞 
DitfaticHi of ruptured membranes >18 hours 
Intrapartum temperature >100.4 F (>38.0 C) 
No 
I 
No intrapartum prophylaxis needed 
*tf membranes ruptured at <37 weeks' gestation, areil the mothm* has not begun labor, collect 
group B streptococcal culture and either a) administer antlbtottcs until cultures are completed 
and the results are negative or b) begin antibiotics only when positive cultures are avaHable. 
T Broader spectrum antibiotics may be considered at the physician's discretion, based on clinical 
Indications. 
Figure 1.2 Criteria for intrapartum prophylaxis by risk-based approach 
(Centers for Disease Control and Prevention, 1996). 
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1.8.2 GBS Vaccine 
lAP has its drawbacks and is unable to prevent late-onset neonatal disease. The scope 
of GBS vaccination is being explored. Immunization with GBS serotype III capsular 
polysaccharide-tetanus toxoid of conjugate vaccine with pregnant women has been 
shown to elicit specific immunoglobulins. The protective immunoglobulin was able 
to cross the placenta and protect the fetus from GBS infection (Baker et al.’ 2003c). 
Potentially, it may reduce preterm delivery, spontaneous abortion, stillbirth (Gibbs et 
al, 2004) and may be applied to specific risk groups to prevent GBS infection in 
adults (Baker et al., 2003a). 
GBS capsular polysaccharide conjugated vaccine has been developed for all 9 
serotypes and found to be safe and immunogenic in humans (Baker et al., 1999; 
Baker et al., 2000; Baker et al.’ 2004; Kasper et al.’ 1996; Paoletti et al.’ 1999; 
Paoletti et al, 2002). In addition to capsular polysaccharide, other surface proteins 
on GBS are also possible targets to elicit protective antibodies. They include the Rib 
protein (Larsson et al, 2004), C5a peptidase (Cleary et al, 2004), and C a and (3 
, proteins (Gravekamp et al.’ 1999; Madoff et al, 1994). Some surface proteins are 
widely distributed on GBS and can synergize with capsular polysaccharide to be the 
carrier and immunogen to increase the coverage of vaccine to most GBS strains 
(Cheng et al., 2002a). 
The development of a pentavalent vaccine to serotypes la, lb, II，III and V is 
theoretically efficient and would cover more than 90% of invasive GBS disease in 
the USA (Harrison et al.’ 1998). A bivalent conjugate vaccine of serotypes II and III 
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has been tested in healthy adults with similar efficiency to their monovalent 
counterparts (Baker et al, 2003b). However, as there is wide geographical variation 
of GBS serotype distribution in the world, e.g the prevalence of serotype VIII in 
Japan but not in other countries (Lachenauer et al,, 1999)，surveillance of the GBS 
serotypes is thus essential for the correct formulation of the vaccine. 
The bivalent conjugate vaccine of serotype II and III have to undergo the phase 3 
trials in pregnant women and neonates, and the liability issues after immunization in 
pregnancies is a major hindrance (Baker et al.’ 2003a). Thus, the GBS vaccine is 
presently still under exploration and not available for prevention. 
1.9 Objectives 
The aims of the project are : (1) To characterize the GBS isolates in Hong Kong by 
phenotypic and molecular methods, (2) develop a rapid molecular method for 
identifying GBS and its serotype from clinical specimens. 
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Chapter 2 Methods and Materials 
2.1 Bacterial isolates 
Three hundreds and seventy GBS isolates selected between 1993 and 2003 April at 
the Prince of Wales Hospital, Hong Kong were stored frozen at -70�C. All bacterial 
strains were isolated from clinical samples including blood cultures, cerebrospinal 
fluid, neonatal screens, vaginal tract swabs, and wound and pus swabs. They were 
categorized into three groups according to their specimen types: invasive, wound and 
colonizing isolates. Duplicate isolates from the same patient were excluded. In 
addition, only 1 isolate was included from each neonate/mother pair from which 
GBS were isolated from both subjects. The number of isolates in each category and 
sample type is listed in Table 2.1. 
All GBS isolates were cultured on Columbia Agar Base (Oxoid, UK) plates 
supplemented with 5% horse blood incubated at 37°C with 5% CO2. All the isolates 
were identified as GBS by their colonial morphology, p-heamolysis, gram stain, 
positive hippurate test, bacitracin resistance, negative bile aesculin test and combined 
Streptex (Murex, UK). Confirmed isolates were further subcultured and saved in 






















































































































































































































































































































































































































































































































Chapter 2 Materials and methods 
2.2 Antibiotic susceptibility test 
The minimum inhibitory concentrations (MICs) of GBS to 10 antibiotics for all 370 
GBS isolates were determined using a microbroth dilution method according to 
National Committee for Clinical Laboratory Standards (NCCLS 2000, M7-A6 Vol 
20 No. 2). Nine antibiotics were tested by microbroth dilution method using serial 
two fold increments of antibiotic concentrations, including penicillin (0.03mg/L -
0.25mg/L), ciprofloxacin (0.25mg/L - 32.0mg/L), gatifloxacin (0.12mg/L — 
16.0mg/L), levofloxacin (0.25mg/L - 32.0mg/L), moxifloxacin (0.12mg/L -
16.0mg/L), lincomycin (0.25mg/L - 32.0mg/L), erythromycin (0.12mg/L -
32.0mg/L), tetracycline (l.Omg/L - 16.0mg/L), chloramphenicol (4.0mg/L -
32,0mg/L) and linezolid (l.Omg/L - 4.0mg/L). Inducible lincomycin resistance 
(0.25mg/L — 32.0mg/L) was performed by agar dilution method. The procedures of 
preparation were described in the following sections. 
2.2.1 Antibiotic preparation 
The nine antimicrobial agents were prepared in concentration of 4000mg/L by 
suitable solvent and diluent as shown in Table 2.2. The antibiotic powder was 
dissolved in a minimal amount of solvent and diluent was added to the target volume. 
The drugs were further diluted to 400mg/L, 50mg/L and 5mg/L as stock solution for 
preparation of different concentrations. An adequate volume of antibiotic from the 
stock solution was prepared as aliquots for microtitre plate preparation. All the 
processes mentioned above were carried out aseptically. 
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Table 2.2 Solvent and diluent of antibiotics 
Antibiotics Source ^ Assay Solvent Diluent Potency (%) 
Cirpofloxacin "^yer, Elberfed" 100 O.lMNaOH dzHzO 
Gatifloxadn BMS 100 — O.lMNaOlT" dzHzO 
Daiichi 
Levofloxacin Pharmaceutical 100 O.lMNaOH diHzO 
Co Ltd, Japan 
Moxifloxacin Bayer，Elberfed 一 87.8 — O.lMNadlT" diHiO 
Lincomycin "sTgma, USA — 100 diRiO diHiO 
Erythromycin Sigma, USA 100 95% Ethanol diHiO 
Tetracycline Sigma, USA 100 DMSO dzHiO 
Penicillin Sigma, USA “ 100 — dzHzO dzHzQ 
Chloramphenicol "^gma, USA — 100 95% Ethanol dzHiO 
Linezolid * ZYVOX, USA 100 - dzHzO — 
* Stock of Linezolid was 2mg/ml solution; NaOH : Sodium Hydroxide 
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2.2.2 Microbroth dilution method 
2.2.2.1 Microtitre plate preparation 
The microtitre plate for MIC determination was prepared by using a Quick Spense 
HE dispenser (Dynatech laboratories, USA). Sterilized Mueller Hinton broth (Oxoid, 
UK) supplemented with 5% lysed horse blood was prepared according to National 
Committee for Clinical Laboratory Standards (NCCLS 2000’ M7-A6 Vol 20 No. 2). 
Presterized dispenser, glasswares and the microtitre plates were use. All preparative 
procedures were performed in a sterile cabinet. The different concentrations of 
antibiotic were added to Mueller Hinton broth with lysed blood to make up to lOOmL 
final volumes. Aliquots of (100|aL) of medium were dispensed in to 96 well 
microtitre plates. All plates were sealed in sterile plastic bags and stored at -70°C 
until used. All plates were used within the month. 
2.2.2.2 Suspension preparation and inoculation 
Colonies of GBS cultures from blood agar plates after overnight incubation were 
inoculated into 4mL Brain Heart Infusion broth (Oxoid, UK). A suspension 
. approximately equal to 3 x 10 cfu/ml (1 Mcfarland), by comparing with 1 
McFarland standard (bioMerieux, France), was prepared. The 4mL of 3 x 10^  cfu/ml 
suspension was 10 fold diluted by mixing with 36mL distilled water to 
approximately 3 x 10^  cfU/ml. 
The inoculation was delivered to microtitre plate by the inoculator MIC 2000 
(Dynatech laboratories, USA). A one point five micro-Litre of 3 x 10^  cfu/ml 
suspension was transferred to the microtitre plate containing antibiotics. 
Approximately 4.5 x lO^ cfu was transferred to the each well of microtitre plate. A 
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loopful of broth from growth control well was subcultured onto blood agar plate for a 
purity check. Both microtitre and agar plates were incubated at 35°C for 20 - 24 
hours. Streptococcus pneumoniae strain, ATCC 49619, was included as a control. 
Each plate included a sterility and bacterial growth control. 
2.2.2.3 End points determination 
The MIC values were determined by observing inhibition of bacterial growth. The 
sterility and growth controls were checked for contamination and growth inhibition 
of bacteria. The end point was assigned to the lowest concentration next to the well 
with bacterial growth. Susceptibility to the antibiotics was determined according to 
MIC interpretive standards from NCCLS 2004 (Vol 24 No. 1 ppl24 - 125). 
Breakpoint for susceptiblity of ciprofloxacin and moxifloxacin were inferred from 
that of other gram positive organisms (NCCLS 2004，Vol 24 No. 1 pp 107 and 122), 
whereas that of lincomycin was according to the French standard CA-SFM (CA-
SFM, 2003). 
2.2.3 Inducible lincomycin resistance determination 
The inducible lincomycin resistance was determined by agar dilution method 
according to National Committee for Clinical Laboratory Standards (NCCLS 2000， 
M7-A6 Vol 20 No. 2). For preparation, lincomycin was dissolved in Mueller Hinton 
Agar (Oxoid, UK) with 5% lysed blood. Agar with lincomycin concentrations of 
0.25mg/L, 0.5mg/L, l.Omg/L, 2.0mg/L, 4.0mg/L, 8.0mg/L, 16.0mg/L and 32.0mg/L 
were freshly prepared and kept at 4°C before use. Before inoculation, the agar plates 
were prewarmed in a 35°C incubator for most at 45 minutes. 
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One point five micro-Litre of 10? cfU/mL suspension was inoculated in lOOjiL Brain 
Heart Infusion broth (Oxoid, UK) containing O.lmg/L erythromycin. The suspension 
was incubated overnight at 37°C with 5% CO2. The erythromycin treated GBS 
suspension was inoculated on agars with 0.25mg/L - 32.0mg/L lincomycin by the 
MIC 2000 inoculator (Dynatech, USA). Streptococcus pneumoniae strain, ATCC 
49619，was included as a control for the antibiotic susceptibility testing. The MIC 
values were assigned to the lincomycin dilution without bacterial growth on the agar 
surface only. 
2.3 Serotyping 
2.3.1 Preparation of antigens 
The serotypes of GBS were determined using the GBS antigen extraction kit and 
antisera produced by Denka Seiken (Denka Seiken, Japan). Nine types of antisera la, 
lb, II - VIII were included (Denka Seiken, Japan). The typing method was as 
according to the manufacturer with minor modifications. The volume of reagent and 
GBS suspension used were reduced from the suggested volume to 25|iL of enzyme， 
. 5 | IL phenol red and 8|liL of pH adjuster. One mini-Litre instead of 5mL, as suggested 
by the manufacturer, overnight culture in Todd Hewitt broth was used for antigen 
extraction. 
A colony of the GBS isolate was inoculated in 5mL Todd Hewitt broth (Oxoid, UK) 
and the bacterial suspension incubated at 30°C overnight in an ambient air incubator 
to reduce auto-agglutination. One mini-Litre of the suspension was centrifuged at 
8000 rpm (Micro centaur, Sanyo, Japan) for 5 minutes. The supernatant was 
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discarded and the pellet was re-suspended in lOOul Todd Hewitt broth. Twenty five 
microlitres of swine pancreas extract and 5|iL phenol-red indicator were mixed with 
the bacterial suspension. The pH of the mixture was calibrated by pH adjuster, which 
was provided in the kit, to pink colour. Pink colour of the mixture was determined 
after 15 minutes incubation. If the colour turned pale pink or orange, the pH adjuster 
was added until the pink colour returned. The mixture was incubated at 37 °C for 1 
hour with occasional shaking. After incubation, the mixture was centrifuged at 8000 
rpm (Micro Centuar, Sanyo, Japan) for 5 minutes and supernatant was discarded. The 
pellet was re-suspended in lOO i^L phosphate-buffered saline. After that, the 
suspension was heated at 120°C for 30 minutes by heat block (Thermolyne Dri-Bath, 
Sybron). The heated mixture was centrifuged at 8000 rpm (Micro Centuar, Sanyo, 
Japan) for 5 minutes, the supernatant was removed and the pellet was finally re-
suspended in lOOjiL phosphate-buffered saline. 
2.3.2 Typing of isolates 
Serotyping was done on a degreased glass slide. The prepared antigen was mixed 
with normal saline (7% sodium chloride) to test for auto-agglutination. If auto-
agglutination was found, the antigen was not used. The prepared antigen was mixed 
with an equal volume of antiserum using a platinum wire for observing agglutination. 
2.4 Pulsed-field Gel Electrophoresis (PFGE) 
, The procedure was modified from that of Benson and Ferrieri (Benson et al., 2001). 
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2.4.1 Preparation of DNA plug for PFGE 
A fresh colony was spread on a blood agar plate and incubated at 37°C with 5% CO2. 
Bacterial suspension was prepared by suspending inoculum from blood agar into 
Tris-EDTA buffer 1 (TEl). The bacterial suspension was calibrated to 4.0 - 5.0 
McFarland by adjusting the optical density (OD) at 550nm to 1.0 - 1.25 by 
spectrometry as according to manufacturer's recommendation of McFarland standard 
(bioMerieux, France). 
One mini-litre of the adjusted bacterial suspension was centrifuged and re-suspended 
in 90uL TEl. Lysozyme (SIGMA, USA) was added to the suspension to a final 
concentration of Img/mL. The suspension was mixed and incubated at 37°C for 15 
minutes. After incubation, 2\xL of Proteinase K (50mg/mL) (USB, UK) was added to 
the suspension. The suspension was thoroughly mixed with equal volume of 55°C 
molten Low Melting Point agarose (Cambrex, USA) and injected into the plug mould. 
The plug was cooled to solidify and was transferred in ImL gram positive lysis 
buffer with 40U mutanolysin (SIGMA, USA). The plug was digested in the buffer at 
3TC for 3 hours. The plug was transferred and further digested in ImL EDTA-n-
lauryl-sarcosine (ES) buffer containing Img Proteinase K (USB, UK) overnight. The 
digested plug was washed in 3mL Tris-EDTA buffer 2 (TE2) for three times at 37 
The buffer was discarded and replaced with fresh buffer. Finally, the washed plug 
was transferred into ImL TE2 for storage. 
2.4.2 Restriction enzyme digestion of GBS DNA 
The plug was cut into slices with 0.1 mini-meter thickness and incubated in lOOjoL 
IX restriction digestion buffer T (Amersham Bioscience, USA) and 0.01% BSA 
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(Amersham Bioscience, USA) without Smal at 30 °C for 30 minutes. The buffer was 
discarded and replaced with 100|uL mixture of IX restriction digestion buffer "T", 
0.01% BSA and 20U Smal (Amersham Bioscience, USA). The sample was digested 
at 30°C for 3 hours. 
2.4.3 Running of PFGE gel 
The digested DNA plug slice was inserted in the bottom of well of 1% Pulsed Field 
Certified agarose gel (BioRad, USA). Standard 入-DNA marker (Amersham 
Bioscience, USA) was included for every lane on the PFGE gel. An internal GBS 
serotype III control was also added for each PFGE gel. Both markers and serotype III 
were used for inter- and intra-gel alignment. The well was sealed with 1% molten 
PFGE grade agarose which the gel electrophoresis was carried by CHEF Mapper XA 
with cooling system (Bio-Rad, USA). The electrophoresis was performed in 2 Litre 
0.5X Tris-Borate-EDTA (TBE) buffer for 30 hours at 14 °C with 6V/cm, 120 
inclination, linear ramping factor and switch time from 5 seconds to 35 seconds. The 
gel was stained by l)j,g/mL ethidium bromine for 1 hour and was destained in 
distilled water for 1 hour. The band pattern was captured in TIFF file and analysed 
by Bionumerics version 3.5 (Applied Maths, Belgium). 
2.5 Molecular characterization 
2.5.1 Target genes 
Each GBS isolate was characterized using four categories of genes including 
detection of 7 surface protein genes(Kong et al, 2002a), 7 mobile genetic element 
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genes(Kong et al.’ 2003)，9 antibiotic resistant genes (Gift from Kong, F; ICPMR, 
Westmead, New South Wales, Australia) and the capsular polysaccharide gene by 
polymerase chain reaction (PCR) (Kong et al, 2002b). The serotypes II’ VII and 
subtypes of serotype III were identified by sequencing of capsular polysaccharide 
genes. GBS isolates were classified as serotype VIII if no amplicon was obtained by 
all serotype specific and sequencing primers. The target genes, primer names, 
sequences and other information are listed in Table 2.3 to Table 2.7. All the primers 
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2.5.2 DNA preparation 
A sweep of bacterial culture on blood agar was suspended in 100|iL digestion buffer. 
The suspension was heated at 100°C for 10 minutes and cooled at -70 °C for at least 
1 hour. After that, 400^L Tris-EDTA buffer 3 (TE3) was added. The prepared DNA 
sample was stored in -20 
2.5.3 Master mix preparation 
Any contamination to PCR was prevented as far as possible as recommended by 
Kwok and Higuchi (Kwok et al.’ 1989). The master mix for PCR was prepared in a 
PCR cabinet using filtered tips. The following was the composition of master mix. 
DNA Sample 5.0^iL 
PCR 1 OX Buffer 2.0}iL 
dNTP (2.5mM) 1.0|liL 
Forward Primer (50pmole/)j.L) 0.2|j.L 
Reverse Primer (50pmole/|iL) 0.2|j.L 
Taq Polymerase (5000U/mL) 0.1 \iL 
Double Distilled Water 11.5uL 
Total Volume 20.0uL 
2.5.4 Polymerase chain reaction 
All PCR reactions for molecular characterization except sequencing were amplified 
using the following condition. 
. 9 4 � C 10 seconds ’ 
； 65 30 seconds r 50 Cycles 
72 1 minute J 
15 Infinity 
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Positive controls were assigned to every tube. Negative control with water and 
reagent control were also incorporated in every batch of PCR. The PCR was repeated 
if the controls were discrepant. 
2.5.5 PCR product analysis by agarose gel electrophoresis 
The PCR products were analysed by 1.5% agarose gel (Cambrex, USA) running at 
120V，IX TBE Buffer for 1 hour. The gels were stained by l.Ofag/L ethidium bromide 
(Sigma, USA) solution for 30 minutes. The result was captured by Imagemaster™ 
(Amersham Bioscience, USA). 
2.5.6 DNA sequencing 
The PCR method for serotyping of GBS for serotypes II, VII and differentiating 
subtypes within serotype III is as follows. DNA template was amplified by the 
following condition. 
Master Mix : 
DNA Sample lO.OjxL 
PCR lOX Buffer 5.0|aL 
. dNTP (2.5mM) 2.5pL 
Forward Primer (50pmole/|^L) O.S i^L 
Reverse Primer (50pmole/)j,L) 0.5|aL 
Taq Polymerase (5000U/mL) 0.25^L 
Double Distilled Water 31.25|liL 
Total Volume 50.0|iL 
, PCR condition: 
94 10 s e c o n d s � 
65 30 seconds r 37 Cycles 
72�C 1 m i n u t e J 
15 Infinity 
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The PCR products were sent to Macrogen (Korea) for purification and sequencing. 
The PCR products were purified and analysed in the company by AMPure PCR 
purification kit (Agencourt, USA), sequenced by dye termination method with Big-
dye terminator version 3.1 cycle sequencing kit (AppliedBiosystems, USA), PTC-
225 Peltier Thermal Cycler (MJ Research, USA) and ABI 3730XL Analyser 
(AppliedBiosystems, USA). 
2.6 Data analysis 
2.6.1 PFGE and molecular characters analysis 
The Pulsed-field gel electrophoresis pattern was captured in TIFF file and imported 
in Bionumerics V3.5 (Applied Maths, Belgium). Band patterns of standard X phage 
marker were included in every gel for inter- and intra-alignment. The band patterns 
of samples were assigned. 
2.6.2 Sequences analysis 
‘ The sequences obtained were aligned and analysed by MegAlign 5.0 (DNASTAR 
Inc., USA) with respect to the sequence discrimination method published (Kong et 
al, 2002b). 
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2.7 Molecular identification by real-time PGR 
2.7.1 Bacterial strains 
Eight GBS reference strains (la, lb, II-V, VII，VIII), 9 standard strains of major 
vaginal flora species (Kubota et al, 2002), were included. Because there is no 
serotype VI reference strain, 16 clinical GBS serotype VI strains were tested for 
specificity. The bacterial isolates as listed (Table 2.8). 
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Table 2.8 Reference and standard strains used in molecular identification of GBS 
Species Strain number 
Streptococcus agalactiae la* 
Streptococcus agalactiae lb* H36B 
Streptococcus agalactiae II* 18RS21 
Streptococcus agalactiae III* M781 
Streptococcus agalactiae IV* 3139 
Streptococcus agalactiae V* CJB 111 
Streptococcus agalactiae VII * 7271 
Streptococcus agalactiae VIII * — JM9 130013 
Streptococcus pneumoniae ATCC 49619 
Enterococcus faecalis ATCC 29212 
Streptococcus equisimilis ATCC 12388 
Staphylococcus epidermidis ATCC 12228 
Escherichia coli ATCC 29417 
Streptococcus pyogenes ATCC 19615 
Haemophilus influenzae ATCC 49766 
Streptococus bovis NCTC 08177 — 
Candida albicans ATCC 24433 
* The strains were kindly supplied by G.L. Gilbert, Centre for Infection Diseases and 
Microbiology Laboratory Service, Institute of Clinical Pathology and Medical 
Research, Westmead, New South Wales, Australia. 
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2.7.2 DNA isolation for specimens 
The DNA extraction method was mentioned in Section 2.5.2. 
2.7.3 Design of TaqMan primers and probes 
The GBS capsular polysaccharide gene, named cps, was chosen for serotype 
identification. Owing to absence of full-length cps gene sequences of all 9 GBS 
serotypes (la, lb, II-VIII) in GenBank database during design, sequence alignment 
was performed only between cpsD-cpsG gene of serotype la, lb, II-VII. These 
regions had been described previously for molecular serotyping of GBS (Kong et al.， 
2002b). Sequences were aligned by ClustalW (Version 1.2), which was provided by 
European Bioinformatics Institute (http://www.ebi.ac.uk/clustalw/index.html). The 
region between 6667 to 6809 in GenBank Accession No. AF163833 was identified to 
be unique to GBS. In addition, position 6717 was unique to majority of the serotype 
III (MS III subtype III-l and III-2) published sequences and was chosen as probe 
binding site for serotype differentiation. A primer set was designed to identify GBS 
by PCR amplification. Two probes were designed to confirm identity of GBS and 
detection of serotype III (MS III subtype III-l and III-2). 
The Assay-by-DesignSM Service (Applied Biosystems，USA) for single nucleotide 
polymorphism (SNP) assay was employed for TaqMan primers and probes design. A 
one hundred and fifty nucleotide sequence including the differentiation site was 
submitted according to the protocol from Applied Biosystems. A 77bp sequence was 
selected for amplification. The sequences of the primers and probes are shown in 
Table 2.9. The GBS serotype III (Molecular serotype III subtype III-l and III-2) 
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Specific probe was labeled with VIC dye and named Probe III. The GBS specific 
probe was labeled with 6-FAM dye was named Probe B. � 
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Table 2.9 Primer and probe sequences 
Primers or probes Sequences (5’~>3，)* 
Forward primer “ 6682-CAAGAAGTGTTCATTCAAACGGGTTAC-6708 
Reverse primer ~6758-TCATATGAGAGAAATTTTGACCACTGACAA-6729 
Probe III (GBS 
serotype III 6725-TGAGGTTCQAAGTCTGA-6709# 
specific probe) 
6726-CTGAGGTTCAAAGTCTGA-6709^ 
*Position refers to sequence GenBank accession number AF163 833. 
\jnderlined nucleotide refers to position for serotype differentiation. 
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2.7.4 Cloning of target sequences 
Two primers in Table 2.9 were synthesized by Invitrogen (USA) and used to 
generate an amplicon of the probe binding sequence. Target sequences were 
amplified from extracted DNA of molecular serotypes III-l and III-4 respectively. 
The reaction mix was prepared with IX PCR buffer (Amersham, USA), 125|iM 
dNTP (Amersham, USA), 2U Taq polymerase (Amersham, USA), 20 pmole of each 
primer (Invitrogen, USA) and dzHiO was added to 50uL. The mix was amplified in a 
GeneAmp® PCR System 9700 thermal cycler for 95°C for 5 minutes followed by 
amplifications composed of 37 cycles at 95 ®C for 15 seconds, 60 °C for 30 seconds 
and 72 for 1 minute. The thermal cycling was terminated by 72 for 10 minutes 
and kept at 15�C. The 75 bp PCR product was directly cloned into pCR®2.1-T0P0® 
by TOPO TA Cloning kit (Invitrogen, USA). The recombined plasmid was 
transformed to TOP 10 competent E. colL, plasmid was extracted by rapid plasmid 
extraction kit (Life Technology, USA). The pairs of real-time primers were used for 
screening positive clone. Sequencing of positive clone was performed for confirming 
sequences for both probes. DNA concentration of plasmids was determined by 
absorbance at 260nm by GeneQuant RNA/DNA Calculator (Pharmacia, England). 
The copy number of the plasmid was calculated from absorbance values and the 
method suggested by manual of GeneQuant RNA/DNA Calculator. 
2.7.5 Master mix of real-time PCR 
Five micro-Litres of DNA extract was mixed with 12.5)aL 2X TaqMan® Universal 
PCR Master Mix, 0.625)aL 40X primer and probe mixture. RNase free water was 
added to 25|aL. Real-time PCR was carried out by ABI Prism® 7900HT Sequence 
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Detection System. Standard thermal cycling profile suggested by Applied 
Biosystems was used. The reaction mixture was heated at 50°C for 2 minutes then a 
hot start of 1 cycle at 95 for 10 minutes followed by amplification composed of 40 
cycles of 92°C 15 seconds and 60 for 1 minute. 
2.7.6 Specificity and detection limit 
The specificity of the primers and probes were assessed by 9 GBS serotypes and 11 
non-GBS standard strains. The detection limit of the real-time PGR assay was 
determined by the lowest concentration of 10 fold serial diluted plasmid DNA. Two 
micro-litres of plasmid were used as template in real-time PGR. In addition, the 
detection limit in the presence of vaginal flora was also quantified. Ten fold serial 
dilution were prepared from a 10^  cfu/mL GBS inoculum. 10^  - 10^  cfu GBS were 
added to lOOjiL of 10^  cfu/mL mixture of vaginal flora. A sample without GBS was 
used as negative control. The suspension was centrifuged at 13,000 rpm (Micro 
Centuar, Sanyo, Japan) for 5 minutes. The supernatant was discarded and pellet was 
resuspended in 100|j.L digestion buffer. Genomic DNA was extracted by the method 
previously described (Section 2.5.2). 5|aL of sample was used in real-time PGR 
detection. The GBS detection limit was calculated as the lowest cfu/mL. 
Vaginal swabs for clinical GBS detection were tested for comparison with the 
routine method. Vaginal swabs were first placed in Todd Hewitt broth containing 
gentamicin (8)ag/mL) and nalidixic acid (15fig/mL). A hundred micro-litre of the 
Todd Hewitt broth was aliquoted into sterile vial at the time that the swabs before 
and after overnight 35°C incubation. The aliquots were stored in -20°C until DNA 
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Chapter 3 Results 
3.1 Serotype distribution of GBS 
3.1.1 Serotyping using antisera 
All 370 GBS isolates were serotyped by the agglutination method as described in 
Section 2.3. The number of isolates and percentage belonging to each serotype are 
shown in Table 3.1. All 9 serotypes were present among Hong Kong GBS isolates. 
Serotype III was the commonest serotype (35.4%) followed by la (15.1%), V (14.3%), 
II (12.7%)，lb (9.7%), VI (3.8%), VII (1.1%)，VIII (1.1%) and IV (0.8%). Twenty two 
isolates (5.9%) were non-typeable (NT) by the 9 antisera available. 
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Table 3.1 Serotype distribution in 370 GBS isolates 
Serotype No. of isolates Percentage 
la 56 ‘ 15.1% 
lb 36 — 9.7% — 
II — 47 — 12.70/0 _ 
III - 131 35.40/0 
IV 3 0.8% 
V — 53 — 14.3% — 
VI “ 14 3.80/0 
VII “ 4 1.1% 
VIII - 4 1.1% 
NT 22 “ 5.9% 
Total 370 lOOo/o 
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3.1.2 Serotyping by molecular method 
The molecular serotypes of GBS were also determined by specific PCR on the 
capsular polysaccharide gene {cps) (Section 2.6) into 9 molecular serotypes (MS). 
Serotype III was further sub-divided into 4 subtypes by DNA sequencing of the cpsE 
to cpsG amplified fragment. This method enabled the NT isolates (by serotyping) be 
categorized into specific MS. 
All isolates, except 3，typed by the serotyping method gave identical MS types. A 
serotype lb (ID 292) was classified into MS VI，whilst 2 isolates belonging to 
serotype VII were classified into MS V (ID 83 and 122). A single point mutation was 
observed in a MS II isolate (ID 370)，the location corresponded to nucleotide 2781 of 
Accession No: AY375362. 
All 22 isolates NT by the agglutination method were typed by the molecular method. 
The distribution of the molecular serotypes is shown in Table 3.2. About 40% of NT 
isolates were MS la, 22.7% were MS III, 18.2% were MS V，9.1% were MS VI and 
4.5% were MS lb and II respectively. 
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Table 3.2 Molecular serotype of the non-typaeble isolates 
Molecular Number of GBS ~ 
serotype (MS) Invasive Wound Colonizing Total Percentage 
la 3 1 ~ 5 9 40.9% 
lb 0 0 — 1 — 1 4.5%~~ II 0 1 0 ~~i~ 4.5% — 
III-l 0 1 2 3 ~ 13.6% ~ 
ni-2 0 0 2 29.1% 
n i - 3 0 0 一 0 ~~0~~ 0.0%~~ ni-4 0 0 0 ~~0 0.0% — IV 0 0 0 ""“0 0.0% — 
V 1 0 3 ~ 4 18.20/0— 
V I 0 1 1 ~ ~ 2 ~ 9.1% 
VI I 0 0 一 0 ~ 0 0 . 0 % ~ ~ 
VIII 0 0 0 ~ ~ 0 ~ 0.0% — 
Total 4 4 14 22 100% 
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3.1.3 Molecular subtype of GBS serotype III 
MS III isolates were subdivided into 4 subtypes (111-1’ 111-2，III-3 and III-4) by 
sequencing region of cpsE, cps¥ and cpsG in the capsular polysaccharide operon 
(Section 2.6). An 882 bp DNA amplicon of the above region in 136 MS III isolates 
was sequenced. The nucleotide sequences for subtype differentiation are shown in 
Figure 3.1. The position of nucleotides at the top corresponded to serotype III cps 
gene sequences (Accession Number : AF163833). Molecular subtypes were only 
assigned when the isolate was an MS III isolate and the amplified sequences were 
equal to the subtype specific nucleotides. The predominant subtype was III-l (52.2%), 
followed by III-2 (25.0%), III-4 (17.7%) and III-3 (5.1%) (Table 3.3). The previous 5 
NT isolates fell into subtypes III-l (3 isolates) and III-2 (2 isolates). 
Among the serotypes of MS III，single point mutation in the sequenced region was 
found in 2 isolates (ID 136 and 188). Isolate ID 188 was assigned to MS III subtype 
III-2 with a point mutation corresponding to nucleotide 6133 of sequence with 
accession no. AF163833. Another isolate (ID 136) was MS III subtype III-4 and 
mutation corresponded to 6355bp of sequence with Accession No. AF 163 833. 
» However, the translated amino acid sequence was not altered. 
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TA&AAATAATATTACT & HAjocity 1 1 1 1 r J , 5960 5970 5980 5990 6000 1 J I • • 1 III-l 
J- lll-Z 1 IU-4 ATTTT&ATGAAATC&TAAA&TTA GAT&TTCAATATATCAATCAATGCTCT Hajori^ y 1 1 1 1 r , 6010 6020 6000 6040 6050 1 1 1 I L-16 1® 111-4 ATTTGGTCA&ATATTAAGATTATTCTCCTAACACTAAA^&TAOTTTTACT HajozUy 
' • I I I 6060 6070 6090 6090 6100 1 1 1 I l_ e® «« f^  I1I-3 
0 [£} 1:1-4 TG^ GACAOOAGCTAAG TAAA&GTAA&GTTT&AAAC&A&TATAATGAAAAT Kajority 1 1 1 1 r J y 6110 6120 6X30 6上40 6150 r-| 1 1 1 I u 118 C III-l lie [cj III-2 
0 TT&TCTGGTT&GTTCfcA&T&GTGGTCATCTAGCACACT TCAACCTTTTCA Kajoritjy I I I 1 I C160 «nO 5190 5X90 6200 1 1 I I u 
" e I I I - l 
IfiS I l l — 2 AACCCATTT&OgAA CGI^ &TTACTC AGACTTT&AAC Hajocity 
I • I 
〒 497 base pairs ^ 石 � 218 “！！‘"“！"“. • . . |a| ."“ ~ . . . . II1-1 C . . . . III-2 III-3 III-4 
Figure 3.1 Nucleotide difference in molecular serotype III subtypes (Kong et al, 
2002b) 
The nucleotide position at the top is based on the position of the complete capsular 
polysaccharide operon (Asscess No. : AF163833). The number at right hand side is 
the position of sequenced region，1 was the first nucleotide of the sequenced region. 
The boxed nucleotides are the differentiating nucleotides between subtypes. 
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Table 3.3 Distribution of subtype in MS III 
Molecular serotype III Number of isolates Percentage of molecular 
subtype (N=136) serotype III isolate 
IIM 71 52.2% 
111：2 34 25.0% 
I M 7 5.1% 
III-4 24 17.7% 
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3.1.4 Correlation of serotypes with diseases 
The MS of GBS isolates from the 3 categories of specimen, namely invasive, wound 
swabs and colonizing strains from neonate/pregnant mother were listed in Table 3.4. 
By chi squared test, there is statistical significance in the distribution of MS la and III 
among the 3 groups. MS la was predominantly found in the wound category, while, 
MS III was statistically significant present in the invasive group. 
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Table 3.4 Distribution of molecular serotypes in 370 GBS isolates from Hong Kong 
Number of isolates 
Molecular Total 丁 ： Wound / Colonizing P value (chi 
Serotype No. Pus (neonatal/vaginal 叫二 
(N=370) (w-i乂） (N=62) swab) (N=176) test) 
la ^ 14 18 33 /7<0.01* 
lb 36 11 5 20 ;?<1.00 
11 48 13 7 28 /7<1.00 “ 
111 (1-4) 136 — 73 — 15 — 48 一 /?<0.Q01~ 
III-l 71 — 32 一 8 31 p<020 
in-2 34 17 2 15 p < 0 . 1 0 
ni-3 7 一 4 一 1 2 ；7<1.00 
ni-4 24 20 4 “ 0 p <0.001* 
I V 3 0 2 1 p < 0 . 1 0 
V 翌 16 10 33 ~ p < 1 . 0 0 
V I 17, 4 3 10 /7<1.00 “ 
v n 2 — 1 一 0 1 /7<i.oo 
v n i I 4 I 0 I 2 I 2 p<0.20 
* : Statistical significance obtained 
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3.2 Antimicrobial susceptibility 
3.2.1 Phenotypic method 
The minimum inhibitory concentrations (MICs) of GBS to 10 antibiotics namely 
penicillin, erythromycin, tetracycline, gatifloxadn, levofloxacin, moxifloxacin, 
ciprofloxacin, lincomycin, chloramphenicol and linezolid, were determined. 
The concentration range of antibiotics, 50% and 90% value of MICs and the 
percentage of resistance to the individual antibiotics are listed in Table 3.5. Ninety 
percentages of GBS isolates (331 isolates) were resistant to tetracycline, 23.8% (88 
isolates) to erythromycin, and 15.1% (56 isolates) to chloramphenicol. Resistance to 
gatifloxadn and levofloxacin were 2.4% (9 isolates) and 2.2% (8 isolates) 
respectively. All GBS isolates were susceptible to penicillin and linezolid. Using the 
breakpoint for ciprofloxacin and moxifloxacin as inferred respectively from that of 
Staphylococcus species and Streptococcus pneumoniae (NCCLS, 2004), the 
prevalence of ciprofloxacin resistance was found to be 7.6% (28 isolates) and of 
moxifloxacin 2.2% (8 isolate). The rates of lincomycin resistance (with or without 
induction) were 22.4% (83 isolates) and 16.8% (62 isolates) respectively using the 
breakpoint of <2.0mg/L from the French Society for Microbiology, Antibiogram 
Committee (CA-SFM, 2003). The M I C values of inducible MLSB phenotype was 
enhanced from <0.25 — 2.0 mg/L to 4.0 - >32.0 mg/L. Only 54 isolates were 
erythromycin and lincomycin resistant. Eight isolates were singly lincomycin resistant. 
T^e number of resistant isolates in the invasive, wound and colonizing groups are 
shown in Table 3.6 and the percentage of antibiotic resistance in the respective groups 
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is illustrated in Figure 3.2. Only erythromycin resistance was particularly associated 
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Table 3.5 The MIC 50 and 90 to 10 antibiotics in 370 GBS isolates 
^ C o n c e n t r a t i o n MIC Percentage of Antibiotics resistance* range (mg/L) 50% 90% (N=3"70) 
Penicillin' • 0.03-0.25 ~ <0.03 0.06 0.0(0) 
Erythromycin' —0.12-32.0 <0.12 — 16.0 23.8 (88) 
Tetracycline' “ 1.00—16.0— > 16.0 >16.0 ~ 8 9 . 5 (331) 
Chloramphenicol�一 4.00-32.0— <4.0 16.0 ~ 1 5 . 1 (56) 
Linezolid' — 1.00 — 4.00— < l.Q 2.0 0.0(0) 
Gatifloxacin' “ 0.12— 16.0— 0.25 0.5 2.4(9) 
Levofloxacin' 0.25-32.0 0.5 l.Q 2.2 (8) 一 
Ciprofloxacin: “ 0.25-32.0— 0.5 1.0 7.6 (28) 
Moxifloxacin^ 0.12-16.0 <0.12 0.25 2.2 (8)一 
Lincomycin^ 0.25-32.0 <0.25 > 32.0 16.8 (62) 
1. MICs breakpoint from NCCLS of Streptococcus spp. other than S, pneumoniae. 
2. MICs breakpoint from NCCLS of Staphylococcus spp. 
3. MICs breakpoint from NCCLS of Streptococcus pneumoniae. 
4. French Society for Microbiology, Antibiogram Committee (CA-SFM) (CA-SFM, 
2003) 
* MICs in the intermediate susceptible level were includes as resistant. 
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Table 3.6 Proportion of GBS isolates with respective antibiotics resistance in invasive, 
wound and colonizing sites 
Number of resistant isolates “ 7 T ~ n ^ p value (chi 
Antibiotics Total No. Invasive ° Colonizing squared 
(N=370) (N=132) ^^^^^ (N=176) test) 
Penicillin 0 0 0 0 “ 
Erythromycin ^ 20 — 13 ^ p <0.01*~~ 
Tetracycline ^ 123 — 55 ^ p < l.OO 
Chloramphenicol 56 17 10 ^ ^ < i QQ 
Linezolid 0 0 0 0 __ 
Gatifloxacin 9 2 1 6 ^ < i,qq 
Levofloxacin 8 2 i 5 p < i.qq 
Ciprofloxacin ^ 11 4 Ts p < 1.00 
Moxifloxadn 8 2 2 4 ^ < I .OO“ 
Lincomycin 62 16 11 ^ p < 0 . 2 0 ~ 
* ： Significant; ~ : No value 
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夕 Antibiotics 
Figure 3.2 Percentage of resistance in invasive, wound and colonizing isolates of GBS 
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3.2.2 Detection and distribution of resistance genes 
Seven antibiotic resistance genes and 1 integrase gene of the Tn97 (5-family transposon 
(int-Tn) were examined. The percentages of isolate with the respective resistance 
genes detected are shown in Figure 3.3. The most common resistance gene harboured 
was tet(M) for tetracycline resistance, whilst tet{0) accounted only 7.8% (29 isolates) 
of all tetracycline resistant isolates. Among the genes encoding macrolide resistance, 
the methylase gene erm{B) was the most prevalent, followed by we/A) (7.3%) and 
erm(TR) (3.8%). The mreA gene was also detected by PCR, but was subsequently 
regarded as not an encoding gene for antibiotic resistance of the organism (Clarebout 
et a/., 2001). 
Twenty-five combinations of these antibiotic resistance genes and integrase gene of 
TnPM-family were present among the 370 GBS isolates (Table 3.7). 18 isolates did 
not harbour any of these antibiotic resistance genes examined. The most prevalent 
combinations were tet(M) with or without Tn97d-family integrase gene {int-Tn), 
followed by tet{0) with erm{B), aphAS and aad6; tet(M) with int-Tn and meJ{A); 
tet{M) with int-Tn and erm(TR). Other combinations were sporadic. The distribution 
of antibiotic resistance genes among isolates of different MS is shown in Table 3.8. 
3.2.2.1 Tetracycline resistance 
Tetracycline resistance was identified in 90% (331/370) of GBS isolates (Table 3.5). 
TetiM) was found in 289 tetracycline resistant GBS isolates and detected singly in 
287 isolates (Figure 3.4). Three isolates harboured tet{M) gene were susceptible to 
tetracycline. Both tet{M) and tet{0) genes were found in two isolates. In contrast, 
如(O) was detected singly only in 27 isolates (8.2%). Tet(M) was predominant in MS 
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III subtype III-l, while, tet{0) in MS lb (Table 3.8). Neither of these 2 genes was 
identified in 15 tetracycline resistant isolates (4.5%). Intregrase gene int-Tn ofTnP/6-
family transposon was detected in 250 of 292 tet(}A) harbouring isolates. Whilst, no 
int-Tn was detected in isolates harbouring tet{0) gene, except 1 tet{}A) harboured 
isolate. The Int-Tn gene was detected without tet(}A) gene in 6 tetracycline resistant 
isolates. In reverse, int-Tn was detected in 4 isolates that were susceptible to 
tetracycline, while, 3 of them were harbouring the tet{}A) gene. 
3.2.2.2 Macrolide and lincosamide resistance 
The macrolide resistance genes were determined in the 88 erythromycin resistant 
GBS isolates (Figure 3.5) and the distribution among the MS is illustrated in Table 3.8. 
Methylase gene erm(B) was detected in 43 isolates (48.9%) isolates, the meJ{A) was 
also present in 5 isolates. One isolate harboured erm(B) was susceptible to 
erythromycin. The efflux gene me/A) was singly detected in 22 other isolates (25.0%) 
and was predominantly seen in MS la and V. Another methylase gene erm{TR) was 
detected in 14 isolates (15.9%) and was only present in MS II. None of these 3 genes 
were present in 9 erythromycin resistant isolates, their MICs value varied from 0.5 to 
.. >32.0 mg/L. 
Constitutive MLSB phenotype was observed in 54 erythromycin and lincomycin 
resistant isolates, caused by erm{B) gene was harboured by 35 isolates with 
constitutive MLSB phenotype, M S lb is prevalent. While, erm(TR) gene was present 
in 14 isolates with constitutive MLSB phenotype, those are M S II isolates. Inducible 
MLSB phenotype was found in 24 isolates with sporadic distribution among MS, 8 
isolates carried erm(B) gene. Eleven were inducible lincomycin resistance isolates 
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were susceptible to erythromycin and none of erm{Q) or erm(TR) was found. The 
mechanism of 5 inducible resistane isolates were unknown. 
Twenty-one isolates were erythromycin resistant but lincomycin sensitive, 19/21 
harboured meJ[A) and no erm{B) or erm(TR) was found. 
3.2.2.3 Aminoglycoside resistance 
AphA3 and aad6 were detected in 28 isolates and singly detected in 6 and 4 isolates 
respectively. Both genes were predominant in MS lb. 
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Figure 3.3 Distribution of the antibiotic resistance genes in 370 GBS isolates 
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Table 3.7 Combination and distribution of antibiotic resistance genes 
Antibiotic resistance Percentage of isolates (%) 
genes ^ p value (chi 
^ ^ -R m ^ i ^ Total Invasive Wound strain Colonizing squared test) 
l l l l l l l l ( N = 3 V 0 ) 工 ( N - 6 2 ) strain(N=176) 
• ' ' i :‘ 204 92 30 n <0.001* 
" l l i f e ” ; / ? : 3厂 8 — 10 16 训 0 一 
零 1 7 5 2 10 叫 0 
••敎 t y 画 ; & 14 4 1 9 <1-00 
M j ' K r l ^ t f v ^ 13 3 1 ？ <1-00 
8 6 0 2 --
• ； • _ 5 一 0 1 4 --
• ; V • , r " 1 r ^ 3 i i g ^ 
M M 4 0 3 1 --
• • : : 〉 • 、 • 4 0 _ 0 4 — -
• • ？ 通 ’ 、 ‘ ] 4 2 1 1 --
4 1 0 3 - - — 
• 、 二 _ 2 0 2 0 --
� � A 巧•丄 2 1 ！ 0 ^ _ 
、减丨，•女 7 2 0 ！ ！ --
••_••'” ？ 1 1 0 0 --
" • • g F ^ " ‘ • ~ ~ ~ 0 - 0 1 一 -一 
I c B ^ ^ r [； 1 0 0 ！ --
• 丨 、 • 一 1 0 0 1 --1 0 — 0 1 _ --
々 、 炉 1 0 ！ 0 --
, , _ “ • � 1 0 ~ 1 2 
C 1 1 0 0 -
々 ， _ 1 0 0 1 _ --
T ： 1 0 0 ！ --
T 7 M ^ ‘ I 38 I 9 6 23 I --
• ： Positive ： Negative * ： Statistical significant; -- ： No value 
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Table 3.8 Distribution of antibiotic resistance genes among molecular serotypes 
Molecular Number of isolates 
/ t f ^ ^ m 如(M) tet{0) erm(B) mej{k) erm(TR) aphAS aad6 None (N = 5 /U) — — 
la (65) ~ 5 3 ~ 0 ‘ 1 9 0 _ 0 1 8 
lb (36) ~ 1 4 1 9 20 0 0 19 19 2 
11(48)— 43 - 4 4 4 — 14 — 4 4 1 
III-l (71) - 67 3 11 1 0 9 5 1 
III-2 (34) 32 0 — 1 4 0 0 0 2 
III-3 (7) 2 ~ ~ 2 ~ 0 0 0 0 0 4 
III-4 (24) 23 0 ~ 0 0 0 0 0 1 
IV (3) 3 ~ 0 0 ~ 0 0 0 0 0 
V(59) 49 1 6 9 " 0 ~ 1 1 5 
VI (17) 2 ~ ~ 0 1 0 — 0 1 2 12 
VII (2) 2 0 0 0 0 O O P 
VIII (4) 2 0 — 0 0 0 0 
292 29 44 27 14 34 32 38 
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tet(M) + tet(O) 0.6% (2) "A r N o n e 4.5% (15) 
tet(O) 8.2% (27)—— Mk i i m 
tet(M) 86.7% (287) _ / 
Figure 3.4 Distribution of tetracycline resistance-encoding tet{M) and tet{0) genes in 
331 GBS isolates with tetracycline MIC > 2.0 |ig/mL 
None 10.2% (9) 
erm(B) + mef(A) 5.7% (5) p r - ^ 
X v ^ H 之办 
A 广!“ \ erm(B)43.2%(38) 
erm(TR) 15.9% (14) ‘广;> 
mef(A) 25% 
Figure 3.5 Distribution of macrolide resistance-encoding genes in 88 GBS isolates 
with MIC > 0.25 g/mL erythromycin 
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3.3 Molecular typing 
3.3.1 Pulsed-field gel electrophoresis (PFGE) 
Three hundred and seventy isolates were typed by PFGE and 361 band patterns were 
available. PFGE was unable to type 9 isolates, no fingerprint was observed after 
extending Smal digestion period. 
PFGE band patterns were analysed by Bionumerics Version 3.5 using the Dice 
coefficient method with 1% position tolerance and 1% optimization. The similarity 
matrix was presented by the unweighted pair-group method by using average linkages 
(UPGMA) method. Using a 90% similarity cutoff, three predominant clusters were 
found and are shown in Figure 3.6 to Figure 3.8. In general, PFGE patterns of GBS 
were highly heterogeneous and did not cluster closely among isolates from invasive, 
wound or colonizing groups. Twenty isolates were clustered together in the largest 
cluster, which was named cluster A (Figure 3.6). This cluster included 20 isolates 
identified as MS III subtype III-4. These band patterns gave a maximum of 2 band 
differences using the method of Tenover- (Tenover et al, 1995). Ninety percentages 
(18 of 20) of these isolates were invasive strains and all of them were isolated from 
adult patients. Moreover, half of the cluster was isolates from 1998. 
Eighteen isolates were clustered respectively into the other two clusters, namely 
Cluster B and C. In cluster B, PFGE patterns differed by 3 bands. Only 1 isolate was 
an invasive strain, ten were wound strains. All of them were serotype la except 1 was 
NT/MS lb (No. 124). These isolates were obtained between 2000 to 2002. Cluster C 
belonged to serotype V/MS V isolates except 1 with serotype VII/MS V (ID 113). 
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The reproducibility of PFGE between gels was analysed. Lambda phage markers and 
control strains ATCC 12403 (GBS serotype III) were included in each gel. The inter-
gel variability was examined by clustering the band patterns of marker and control 
strains from each gel by Dice coefficient method with 1% position tolerance and 1% 
optimization setting. The results were presented by UPGMA in Figure 3.9 A and B. 
The similarity of markers between gels was 99.9% and that of control strains was 
99.28%, indicating minimal gel to gel variation of band patterns, and ensuring the 
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Figure 3.9 Dendrogram of inter-gel PFGE markers and standard strains 
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3.3.2 Distribution of GBS surface protein genes profiles 
The detection of seven genes encoding C proteins and members of C a-like protein 
family were performed by PCR (Section 2.5). The most prevalent surface protein gene 
was rib protein gene "R" present in 38.6% (143/370) isolates. The second was genes 
of C a protein and C P protein "AaB" in 57 isolates, followed by C a-like protein 3 
"Alp3" (38 isolates), C a protein "Aa" (34 isolates) and C a-like protein 2 "Alp2as" 
(12 isolates). The other gene combinations were found in 1 isolate respectively. The 
distribution of surface protein genes among 370 isolates and molecular serotypes is 
shown in Table 3.9. 
The repeating unit gene "a" without the C a protein gene was predominant in MS la, 
"Aa" was predominant in MS III subtype 111-4，"AaB" in lb, "Alp2as" in la, "Alp3" in 
MS V，R in MS III-l and MS 111-2. MS la also included most isolates that did not 
harbour surface protein gene. The distribution of other protein genes or combination 
was heterogeneous among serotypes. The distribution of surface protein genes among 
3 categories of isolates are shown in Table 3.10. Only "R", "a" and "Aa" showed 
statistically significant distribution among the 3 categories. "R" and "a" were 





































































































































































































































































































































































































































Chapter 3 Results 
Table 3.10 Distribution of surface protein genes among 3 groups of isolates 
~ S u r f a c e N u m b e r of isolates , , , . ： = ： ———J~~rrri—P value (chi protein Total Invasive Wound Colonizing ^ , 二、 
genes (N=370) (N=132) (N=62) (N=176) squareatest) 
R 143 56 15 72 ~ p < 0 . 0 5 * 
AaB 57 — 17 _ 9 31 1 . 0 0 ~ 
a 55 10 11 — 34 0.025* 
Alp3 38 12 10 16 “ /?< 1.00 
Aa 34 20 6 — 8 /?<0.01* 
None 17 6 5 — 6 p<1.00 
A l p 2 a s 1 2 5 3 4 p<1.00 
as 5 2 2 — 1 p<1.00 
RB 3 0 1 — 2 — -
A 1 0 — 0 1 
Aas 1 1 0 一 0 — - -
AasB~~ 1 0 0 1 -
aB 1 1 0 ~ “ 0 --
A l p 2 1 1 0 0 -
Ralp2 I 1 I 1 I 0 I 0 I --
* : Significant --: No value 
A : C a protein; 
a : C a protein repeating unit; 
as C a-like protein repeating unit; 
B : C (3 protein; 
Alp2 : C a-like protein 2; 
Alp3 : C a-like protein 3; 
R : rib protein; 
None : Neither genes detected 
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3.3.3 Distribution of mobile genetic elements 
Six insertion sequences and one group II intron were examined, and their distribution 
in GBS isolates among molecular serotypes are shown in Table 3.11. The 
predominant mobile genetic elements were ISSagl and lSSag2 and present in 92.7% 
(343/370) and 94.9% (351/370) of GBS respectively. IS1381 was detected in 290 
isolates (78.4%), IS5(57 in 210 isolates (56.8%), GBSil (27.6%), IS1548 (25.4%) and 
lSSa4 (4.9%). None of the 7 mobile genetic genes was found in 17 isolates (4.6%). 
The combinations of the mobile genetic elements present in the isolates are listed in 
Table 3.12. Nineteen combinations of 7 mobile genetic element genes were detected. 
The combination with all 7 genes was not observed. The most predominant 
combination was IS7357 plus ISSagl and lSSag2, and was found in 98 isolates and 
evenly distributed in MS la, III，V and VI. It is significantly distributed {p < 0.05, chi 
squared test) between 3 categories and predominant in wound/pus strains. The 
second predominant combination was IS861 plus IS1548, 187557, ISSagl and 
lSSag2 which was detected from 69 isolates and predominant in MS III subtype III-l 
(66 isolates). The third one was a 4 gene combination, which was IS861 plus IS1381, 
“ ISSagl and IS^ Sag二 and was detected from 41 isolate and predominant in lb (33 
isolates). The others are shown in Table 3.12. 
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Table 3.11 Distribution of mobile genetic elements in different molecular serotypes 
of GBS 
Molecular Number of isolates (N=370) 
Serotype GBSil IS脇 1SJ3SJ ISSaV IS^Sag/ | I S ^ S a f 
la — 11 ‘ 0 0 28 0 45 48 
lb — 0 0 33 36 1 36 36~~ 
II 29 ~ 3 ~ 42 48 17 — 46 _ 48 
III-l 0 71 ' 70 — 71 0 68 70 
III-2 34 0 34 0 0 34 34 
III-3 一 1 0 一0 1 一 0 7 7 一 
III-4 1 0 ~ 3 24 0 23 24 
IV 0 0 “ 0 ~ 3 0 3 3 
V 23 20 25 56 0 — 58 — 59 
VI 3 0 ~ 0 ""“17 0 17 16 
VII 0 — 0 1 2 0 ~ 2 2 
VIII 0 ~ 0 2 4 0 — 4 4 



































































































































































































































































































































































































































































































































Chapter 3 Results 
3.4 Analysis based on PFGE, surface protein genes， 
mobile genetic elements and antibiotic resistance 
genes 
Analysis between PFGE, surface protein genes, mobile genetic elements and 
antibiotic resistance genes were examined under individual serotypes analysed using 
Bionumerics Version 3.5. PFGE was analysed by Dice coefficient with 1% position 
tolerance and 1% optimization. Surface protein genes, mobile genetic element genes 
and antibiotic resistance genes were analysed by simple matching method separately. 
The combination of similarity matrix of PFGE, surface protein genes, mobile genetic 
elements and antibiotic resistance genes were done by an averaging method and the 
output dendrogram was presented by UPGMA. The dendrograms with the detailed 
information are placed in Appendix II: Dendrograms. 
3.4.1 Intra-molecular serotype 
3.4.1.1 Molecular serotype la 
A total of 65 isolates belonging to molecular serotype la was included for analysis. 
Four clusters were identified，they were named la-A, B, C and D according to 
decreasing clustal size. The dendrogram is shown in Figure 3.10 (Complete details in 
Appendix II: Dendrograms). 
The largest cluster la-A included 28 isolates and fell into 90% similarity. 
..Predominant isolates had indistinguishable PFGE patterns and all had < 4 band 
differences, isolates were isolated between year 2000 to 2002. The gene of C a 
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protein repeating unit "a" was detected in 25/28 isolates, no C a protein N-terminus 
gene was detected. These isolates were characterized by the presence of IS1381, 
ISSagl, lSSag2, tetracycline resistance with tet{M), and were susceptible to other 9 
antibiotics, except for a small group of 5 isolates in which erythromycin resistance 
was associated with the presence of meJ{A) gene. Integrase gene int-Tn of Tn97(5 was 
detected in these 5 isolates. All, except 2 isolates, were from colonizing and wound 
sites. One isolate was from bacteriemia in a mother, and another from neonatal 
meningitis case. The latter strain was resistant to tetracycline and 4 fluoroquinolone 
antibiotics. 
Eighteen isolates were clustered at 80% similarity in cluster la-B. Six strains were 
isolated from sterile site, 3 from wound and 9 from colonizing sites during 1996 -
2003. PFGE patterns of this group differed from 2 to 7 band differences, majorly 3, 
but these strains were characterized by not harbour mobile genetic elements or 
surface protein genes. The antibiotic resistance profile and resistance genes 
distribution were heterogeneous. All the invasive strains were isolated from adult, 
with either diabetes mellitus or cirrhosis of liver. 
In cluster la-C, nine isolates from 1994 to 2002 were included. The PFGE patterns of 
this cluster were less homogeneous, with 2 to 5 band differences among isolates, but 
the isolates characteristically possess the C a protein repeating unit "a", group II 
intron GBSil, ISSagl and lSSag2. Generally this cluster was only resistant to 
tetracycline. The resistant gene tet{M) was detected in most of the tetracycline 
..resistant isolates. 
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Cluster la-D included seven isolates from invasive and wound swabs of adults only. 
The gene of C alpha-like protein 2 {alp2) as well as ISSagl and ISSag2 were present. 
Nearly all isolates were tetracycline resistant and were encoded by the tet(M) gene, 
and likely to be carried by the transposon of Tn97(5-family. 
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3.4.1.4 Molecular serotype III 
Thirty-seven isolates belonged to molecular serotype lb. The dendrogram is 
illustrated in Figure 3.11 and Appendix II. These isolates were characterized by 
carrying C a and P proteins, IS567, IS1381, ISSagl and lSSag2 and tetracycline 
resistance. They were split into two major clusters by the presence either of tet{M) in 
cluster Ib-B or tet{0) gene plus erm{B), aphAS and aad6 genes in cluster Ib-A. 
Cluster Ib-A included 19 isolates from 1999 to 2003 and are closely related isolates 
with PFGE patterns that differ by < 3 bands, and are isolates from colonizing, wound 
and invasive sites. All isolates except 4，were resistant to erythromycin and 
lincomycin. All tetracycline and erythromycin resistance in this cluster carried the 
tet{0) and 'erm{B) genes respectively, except for 1 isolate. Moreover, kanamycin 
resistance gene aphAS and streptomycin resistant gene aad6 also were generally 
found in this cluster. An isolate with multiply resistance to erythromycin, tetracycline, 
lincomycin and fluoroquinolones was found. 
Cluster Ib-B included 9 isolates from 1994 to 2002. The surface protein genes and 
mobile genetic element were similar as in cluster Ib-A. All Ib-B isolates were 
tetracycline resistant, but tet(M) gene instead of tet(0) was detected in this whole 
cluster. Integrase gene int-Tn was found in all tet(M) positive isolates. Other resistant 
genes were not detected and isolates were susceptible to erythromycin and other 8 
antibiotics. 
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3.4.1.3 Molecular serotype II 
Forty-eight isolates belonged to MS II. The dendrogram is shown in Figure 3.12. 
These isolates carried the IS1381, ISSagl, lSSag2, tet{M), int-Tn genes and were 
resistant to tetracycline. Three clusters could be distinguished by their surface protein 
genes and resistance genes. These strains were seen from all 3 groups of isolates. 
Cluster II-A included 19 isolates from 1995 to 2002 from all sources, but all except 
two isolates were obtained from neonates and pregnant mothers. Isolates had 
indistinguishable PFGE patterns and were differed from the other clusters by 
presence of rib protein gene "R", GBSil and IS86J genes. Moreover, they were 
susceptible to all antibiotics except tetracycline. 
Cluster II-B included 15 isolates from 1996 to 2002, PFGE patterns were 
indistinguishable. This cluster was dominated by colonizing strains and were 
characterized by carrying genes of C a and p protein, ISSa4, erm(TR), 
erythromycin and lincomycin resistance. Similar to cluster II-A, a high proportion of 
isolates (10/15) were obtained from maternal and neonatal sources. The 5 invasive 
• cases were from adults between 32 - 84 years of age. 
Cluster II-C included 4 isolates from 2000 to 2002. The PFGE pattern, surface 
protein gene, mobile genetic and antibiotic resistance genes were similar to cluster II-
A except these carried additional resistance genes of erm(B), meJ{A), aphA3，aad6 
and resistance to erythromycin, lincomycin and chloramphenicol. Three of the four 
isolates were obtained from maternal and neonatal sources. 
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3.4.1.4 Molecular serotype III 
A hundred and thirty-six MS III isolates from 1993 to 2003 were included. The 
dendrogram is illustrated in Figure 3.13 and continue in Figure 3.14. These isolates 
were common in carrying ISSagl, lSSag2, tet(M) and int-Tn genes. These isolates 
were divided into 6 major clusters with characterized PFGE patterns, surface protein 
and mobile genetic element genes. 
Cluster III-A included 49 isolates from 1993-2003. Their PFGE patterns were less 
indistinguishable than the other clusters, and differ by up to 9 bands difference from 
the common fingerprint. However, all these isolates harboured IS861, IS1548 and 
IS1381 and were identified to be MS III subtype III-l. They were generally 
susceptible-to the tested antibiotics except tetracycline with the presence of tet{M) 
and int-Tn genes. Three of these strains (ID 102, 253, 337) were also resistant 
fluoroquinolones. 34 of 49 isolates were obtained from maternal and neonatal cases. 
A predominance of invasive isolates (22/49) was seen in this cluster, 13 were from 
matemal/neonatal diseases, whilst another 9 belonged to non-pregnant bacteriemia. 
.� Cluster III-B included 34 isolates from 1993 to 2002 and had indistinguishable PFGE 
patterns. These isolates were characterized by harbouring rib protein "R", GBSil and 
IS861 genes. Almost all isolates were tetracycline resistant and carried tet{M) gene, 
half of them were resistant to chloramphenicol. Majority of these isolates were from 
maternal and neonatal cases (30/40) and 50% (17) isolates were invasive. 
Cluster III-C included 34 isolates from 1995 to 2003. Isolates had indistinguishable 
PFGE pattern and distinct from cluster III-A and III-B. The cluster was characterized 
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by carrying C a protein "Aa" rather than rib protein "R" gene. The whole cluster was 
only resistant to tetracycline with the presence of teti^A) and int-Tn genes. All except 
1 isolate (ID 214) were MS III subtype III-3. These isolates were all obtained from 
adults, 20 isolates were invasive and 4 were wound isolates and no colonizing strain 
was found. Moreover, 11 of 20 invasive isolates were isolated in 1998 suggesting a 
cluster of invasive GBS disease in non-pregnant adults. 
Cluster III-D included 9 isolates from 1995 to 2002 and were identified as MS III 
subtype III-l. These isolates generated multiple Smal restriction fragments on PFGE, 
but included mainly (8/9) adult cases of GBS diseases. 
Cluster II，E included 10 isolates from 2000 to 2002 and were identified as MS III 
subtype III-l. These isolates harboured equal surface protein and mobile genetic 
element genes as cluster III-A，but expressed the M L SB phenotype and carried the 
erm{B) gene. 
Cluster III-F included 7 isolates from 1995 to 2002. These isolates were generally 
, susceptible to the tested antibiotics and harboured the C a protein repeating unit-like 
unit "as" and alp2 protein genes. 
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3.4.1.4 Molecular serotype III 
Fifty-nine MS V isolates were included and all were typed V by the serological 
method except 4 which were non-typeable and 2 were typed as VII by the serological 
method. The dendrogram is shown in Figure 3.15 and Appendix II: Dendrograms. 
These isolates were generally carrying genes of IS1381, ISSagl, \SSag2. 
Tetracycline resistance was commonly detected with the presence of tet(M) and int-
Tn genes. They were split into 3 clusters by the presence of different surface protein 
and mobile genetic element genes. 
Cluster V-A included 31 isolates from 1994-2002 and had indistinguishable PFGE 
patterns. This cluster was characterized by the presence of alp3 gene. Isolates were 
susceptible to all antibiotics except tetracycline. Four isolates expressed the MLSB 
phenotype and carried the erm{B) gene. 20 of 31 isolates were isolated from maternal 
and neonatal sources. All invasive strains were isolated from adults. Interestingly, 
one of the isolate which was serotype VII by serological method showed 
indistinguishable PFGE and identical surface protein and mobile genetic elements, 
suggesting possible a capsular switch only in its genetic makeup. 
Cluster V-B included 19 isolates from 2000 to 2002 and had variable PFGE pattern. 
These isolates were characterized by carrying rib protein "R", GBSil, IS5(57 and 
IS1548 genes. All strains didn't show beta-haemolysis on horse blood agar. All of 
them were tetracycline and chloramphenicol resistant with the presence of tet(M) and 
int-Tn genes. Nine isolates were also erythromycin resistant with the meJ{A) gene. 
This cluster made up of high proportion (14/19 isolates) of colonizing strains of 
neonate and pregnant mother. 
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Cluster V-C included 8 isolates from 1995-2003. Isolates had PFGE pattern similar 
to cluster V-B but characterized by carrying C a protein repeating unit "a" without 
presence of C a protein gene and GBSil gene. The whole cluster except 1 was 
resistant to erythromycin and lincomycin, and susceptible to other antibiotics. 
Similar to the other two clusters, most isolates in cluster V-C were obtained from 
maternal or neonatal sources. 
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3.4.1.6 Molecular serotype VI 
Sixteen MS VI were included, two were non-typeable by serology and one was typed 
as lb by agglutination. The dendrogram is shown in Figure 3.16. The MS VI isolates 
were generally characterized by the presence of C a protein, IS1381, ISSagl, lSSag2. 
Their PFGE patterns with 2 to 3 bands difference among 12 of 16 isolates, these 
were colonizing strains from maternal and neonatal cases. The antiserum typed lb 
strain was indistinguishable to MS VI isolates in the surface protein, mobile genetics 
element genes. This cluster was mainly susceptible to all antibiotics except for 2 
isolates (ID 114 and 292). 
3.4.1.7 Molecular serotype IV, VII and VIII 
The dendrogram of MS IV，VII and VII is shown in Figure 3.17 and MS IV included 
2 wound and 1 colonizing isolates. The PFGE patterns were heterogeneous, but all of 
them carried the alp3 gene, IS7357, ISSagl, lSSag2, tetQA), int-Tn genes and 
resistance to tetracycline and susceptible to other antibiotics. 
Two MS VII and four MS VIII were identified correlated to typing by serological 
method. Their PFGE patterns were differed by 1 to 4 bands and presence of surface 
protein, mobile genetic elements and antibiotic resistance genes were heterogeneous. 
Generally, these isolates were resistant only to tetracycline with the presence of 
tet(M) likely on transposon of Tn976-family. 
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3.4.1.8 Non-typeable isolate (NT) 
Twenty-two NT isolates were identified by molecular method as molecular serotype 
la, lb, II, III，V and VI. Four of them were invasive isolates, 4 were wound isolates 
and 14 were isolated from colonizing site. Generally, the PFGE pattern, surface 
protein mobile genetic elements and antibiotic resistant genes were heterogeneous. 
The dendrogram is shown in Figure 3.18. Most of isolates were resistant to 
tetracycline and sensitive to other antibiotics. Sixteen of 22 NT isolates were 
obtained from maternal or neonatal cases and included both invasive and colonizing 
strains. 
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3.4.2 Analysis of Maternal and neonatal strains 
All maternal and neonatal isolates (231 isolates) were grouped for analysis. Neonatal 
isolates included 33 invasive strains, 1 wound strain and 76 colonizing strains. While, 
maternal colonizing strains (100 isolates) and invasive strains of pregnant mother 
with maternal fever (21 isolates) was included. 
The distribution of invasive strains among molecular serotype of neonatal and 
maternal isolates was shown in Table 3.13 and Table 3.14. MS III isolates were 
significantly predominant in neonatal invasive strains, especially MS III-l and 111-2， 
while, MS V was predominant in neonatal colonizing strains. Simultaneously, MS III 
isolates were also significantly predominant in invasive strains of matemal/neonatal 
group. 
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Table 3.13 Distribution of neonatal invasive strain among molecular serotypes 
, ^ , � T … � Invasive . p value (chi Molecular serotype Total (N=l 1 0 ) 例 = 3 3 ) invaswe squared test) 
一 la — 16 2 14 <0.10 
— lb 6 1 — 5 <1.00 — 
— II 17 2 15 <0.10 — 
— 1 1 1 ( 1 - 4 ) 一 43 26 1 7 ~ ~ <0.001* 
I I I - l 28 14 14 — <0.01* 
— III-2 一 14 11 3 <0.001* 
~ III-3 1 1 0 ~ < 0.20 
— III-4 0 0 ~ 0 ~ 
IV 1 0 1 ：：： 
— V — 21 2 ~ ~ 1 9 < 0.025* 
VI 5 — 0 ~ • 5 “ 
— VII 0 0 ~ 0 -- — 
— VIII 1 I 0 I 1 I --
* : Statistical significant; ~ : No value 
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Table 3.14 Distribution of maternal and neonatal invasive strains among molecular 
serotypes 
1 1 . � 1 / X T 1 , 1 � Invasive . ~卯 p value (chi Molecular serotype Total ( N = 2 3 1 ) � = 5 4 ) m v a s i ^ squared test) 
一 la 一 38 5 33 0.2 
— lb 一 22 — 1 2 0 ~ 0.1 
— 11 一 34 6 2 8 ~ 1 
— 1 1 1 ( 1 - 4 ) 一 81 33 48 — <0.001* 
III-l — 48 17 31 <0.05* 
III-2 一 30 15 ~ ~ 1 5 ~ ~ <0.001* 
— III-3 一 3 1 2 1 
— III-4 0 0 — 0 -- — 
— IV 1 0 1 - — 
— V 一 41 7 34 1 
— VI 11 — 1 10 1 
— VII 0 0 0 -- 一 
— VIII 3 I 0 I 3 I -
* : Statistical significant; ~ : No value 
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3.4.3 Comparison of GBS strains from Hong Kong to 
Australia and Korea 
370 GBS strains were compared to GBS database of 260 Australian strains, 196 
Korean strains, while 49 isolates had no geographical information (Fanrong Kong 
and Gwendolyn L. Gilbert, Centre for Infectious Diseases and Microbiology 
Laboratory Services, Institute of Clinical Pathology and Medical Research, 
Westmead, New South Wales, Australia, unpublished data). The comparison was 
carried through by molecular serotype, PFGE fingerprint, 5 surface protein genes of 
C a protein, C a protein repeating unit/repeating unit-like unit, C (3 protein, rib 
protein, alp2 and alp3 proteins) and 5 mobile genetic elements (GBSil, IS861, 
IS1548, IS1381, lSSa4). 
Among MS la strains, most of the Australian and Korean strains were clustered with 
cluster la-A strains. While cluster la-B, C and D were relatively unique in Hong 
Kong, only few Australia or Korea strains were clustered with these three clusters. 
The cluster Ib-B was indistinguishable to Australian and Korean strains, on the other 
hand, cluster Ib-A was unique that only Hong Kong isolates were clustered. Two 
clusters described in MS II strains are generally present in Australia and Korea, 
however, the Hong Kong strains were relatively predominant. MS III strains were 
predominant in the combined database, cluster III-A, B, D and E were generally 
present in three countries. While, the cluster III-C, MS III-4 strains, is unique in 
Hong Kong, none of the Australian and Korean strains were clustered with this strain. 
MS IV strains were in small number among three countries, however, the 3 Hong 
Kong MS IV strains were unique and distinguished by carrying surface protein alp2 
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gene. Among MS V isolates, comparable Australian and Korean strains were cluster 
together with cluster V-A isolates. Cluster V-B strains harboured GBSil, IS861, 
IS1548 and IS1381, were unique among the isolates. While cluster V-C is also 
unique to Hong Kong, except clustered with 1 Korean isolate. Generally, MS VI，VII 
and VIII isolates from three countries were indistinguishable after clustering. 
> 
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3.5 Molecular identification of GBS by real-time 
PGR 
3.5.1 Specificity 
Eight GBS standard strains including la, lb, II，IV，V VII，VIII and two different 
strains of serotype III were tested. Representatives of serotype VI clinical isolates 
were also included. 
All tested isolates, except serotype VIII，were positive to either Probe B or Probe III 
(Table 3.15). The specificity of the assay was also performed, using non-GBS 
‘standard strains from Table 2.8 (Section 2.7.1). DNA extraction was confirmed by 
PCR on 16S rRNA, and none were positive to the probes, while the the two positive 
controls, la (090) and III (M781), were correctly detected by the respective Probe III 
andB. 
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Table 3.15 Real-time PCR result on GBS standard strains and clinical serotype VI 
isolate 
Probe III Probe B~~ 
Sample Name Threshold Threshold 
cycle cycle 
la (090) _ -- 25.6 
一 lb (H36B) -- 21.5 
— II(18RS21) - -- 21.0 一 
_ III (M781) 26.0 --
Reference strains IV (3139) -- — 24.6 — 
— V ( C J B l l l ) — -- 26.1 
— VII (7271) - - 30.3 — 
— V I I I (JM9 130013) “ ~ 
III (ATCC 12403) - 35.9 
Clinical serotype VI (No. 4) - 19.7 
Clinical serotype VI (No.31) - 23.0 — 
Clinical serotype VI (No.65) - 27.8 — 
Clinical serotype VI (No.71) -- 28.8 — 
“Clinical serotype VI (No. 1 - - 31.4 
“Clinical serotype VI (No. 1 m T - 28.5 
Clinical serotype VI (No. 1 2 ^ - 一 31.0 
"Clinical serotype VI (No. 169)“ -- 21.8 — 
Clinical serotype VI (No.211) - 28.6 — 
Clinical serotype VI (No.225) - 27.0 
Clinical serotype VI (No.256) -- 28.6 
Clinical serotype VI (No.3 f ^ - 26.1 
"Clinical serotype VI (No.327)~ - 30.5 — 
Clinical isolates Clinical serotype VI (No.335) -二 22.8 
Clinical serotype VI (No.338) -- 一 33.6 
Clinical serotype VI (No.340) - — 30.4 — 
MS la (No.48) - 21.3 “ 
. MS lb (No.35) 一 - 一 18.2 
MS II (No. 12) 一 - 19.6 
— MS III-l (No.2) — 22.0 — - ~ 
• MS III-2 (No. 145) 一 26.5 -
— MS III-3 (No.214) — - 26.4 — 
— MS III-4 (No. 13) - — 18.0 — 
— MS IV (No.62) — - 23.9 一 
— MS V (No. 10) - — 20.7 — 
MS VII (No.83) - 23.9 
. MS VIII (No. 109) -- --
Probe B positive control 24 g 
n ••‘ ^ 1 serotype la (090) • 
Positive controls ” 广 � - — — ： 
Probe III positive control 州� 
serotype III (M781) “ 
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3.5.2 Detection limits 
The sensitivity of the assay was evaluated using DNA templates of plasmids 
containing the 2 sequences of MS III-l and III-4. The amplification plots of the 
cloned DNA fragments are shown in Figure 3.19 and Figure 3.20 respectively. The 
number of copies in real-time PCR reaction are 38.6 copies and 54.2 copies in 2uL, 
and detection limits of the assay for both probes were 19300 copies/mL and 27100 
copies/mL respectively. 
The detection limit was determined on bacterial culture prepared by 10^  cfu/mL 
vaginal flora suspension spiked with known amount reference strains, either GBS la 
(090) or III (M781). DNA extraction was preformed using method in Section 2.5.2. 
• The limits'of detection in the presence of vaginal flora were 1 x 10^  cfu/mL and 
1.925 X 105 cfu/mL for GBS III and la respectively. 
The detection limit testing was repeated using vaginal tract specimens spiked with 
reference strains, either GBS la (090) or III (M781) and DNA extraction was 
preformed using method in Section 2.5.2. The limits of detection in the presence of 
• vaginal flora was 2 x 10^  cfu/ml and 2.8 x 10^ cfu/mL for III (M781) and la (090) 
using the Probes III and Probe B respectively. In addition, 5 clinical vaginal 
specimens were tested by the assay, one was positive to Probe III. No GBS was 
identified from all the specimens by the routine laboratory, 
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Figure 3.19 Amplification plot of Probe III 
1 denotes 3.86 x 10^ copies of plasmid 
2 denotes 3.86 x copies of plasmid 
3 denotes 3.86 x 10^ copies of plasmid 
4 denotes 3.86 x 10^ copies of plasmid 
5 denotes 3.86 x 10' copies of plasmid 
123 
Chapter 3 Results 
Amplification Plot 
Amplification Plot 
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Figure 3.20 Amplification plot of Probe B 
1 denotes 5.42 x 10^ copies of plasmid 
2 denotes 5.42 x lO^ copies of plasmid 
3 denotes 5.42 x 10^ copies of plasmid 
4 denotes 5.42 x 10^ copies of plasmid 
5 denotes 5.42 x 10^ copies of plasmid 
6 denotes 5.42 copies of plasmid 
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Chapter 4 Discussion 
4.1 Laboratory methods for typing and 
characterization of GBS 
4.1.1 Serotyping by agglutination and molecular method 
Serotyping is the classic and fundamental step to categorizing GBS isolates. 
However, typeability was limited only to 9 serotypes, and a proportion was non-
typeable (NT). These NT strains have previously been explained by the inactivation 
of capsular polysaccharide genes by insertion sequences IS J 548 or IS861 (Sellin et 
al., 2000), phase-shift of capsular polysaccharide low density (Sellin et al, 1995), 
• decreased capsular polysacharride expression (Palacios et al, 1997) or even the 
emergence of new serotype (Slotved et al, 2002). The ratio of NT isolates in 
different countries varied. Our study indicated 5.9% of Hong Kong isolates were 
non-typeable, whereas some countries such as Taiwan (13.1%) and Japan (9.6%) 
have reported much higher percentages (Ko et al., 2001; Lachenauer et al, 1999). 
Serotyping alone was unable to indicate the pathogenicity of GBS (Dore et al, 2003; 
. Lammler et al., 1995; Valentin-Weigand et al., 1995). Although serotype III has 
been widely accepted to relate to invasive diseases, only two subtypes of serotype III 
were suggested to be important (Bidet et al, 2003; Granlund et al, 1998). 
The molecular method of "serotyping" correlated extremely well with the serotyping 
by agglutination (Section 3.1.2). In addition, it enabled all isolates to be allocated to 
an equivalent "serotype", thus providing an alternative convenient and accurate 
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method of typing GBS. It eliminates the costs of the antisera and the cumbersome 
method of extraction of the capsule for serotyping. 
In this study, discrepancies were observed in 1 serotype lb being identified as MS VI 
and 2 serotypes VII isolates being identified as MS V (Section 3.1.2). The 
mechanism for this variation is unknown. Previous report indicated a minor variation 
between serotype la and III capsular polysaccharide synthesis processed, an 
alteration of a single gene was sufficient to make this capsular polysaccharides 
change (Chaffin et al.’ 2000). The mechanism should be further elucidated and is 
important as serotype is still the classical and critical typing method for GBS, and the 
discrepancies will affect comparisons using antisera for serotyping and ultimately 
also in the.vaccine formulation. 
Comparing the structures of serotypes lb and VI polysaccharide repeating unit, both 
have an identical disaccharide backbone, and differ in the capsular polysaccharide 
repeating unit by a substitution of N-acetylglucosamine in serotype lb for glucose in 
serotype VI and the linkage of repeating unit (Figure 4.1). This variation in sugar 
molecule linkage had been suggested to be due to a change in cpsR, cpsl, cps] and 
cpsK genes (Cieslewicz et al, 2005). Since specific PCR and sequence targeted on 
capsular polysaccharide gene cpsE to cpsG, cpsE and cpsl (Section 2.5) indicate the 
isolate contained MS VI genetic content, it is possible that a serotype VI isolate had 
acquired the cps] and cpsK genes of lb, and this resulted in the discrepancy. 
On the other hand, 2 antiserum V isolates were typed MS VII by the molecular 
method. It is possible that an MS VII isolate (ID 113) loss or inactivation of the cpsO 
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gene of serotype V. The polysaccharide repeating units of serotype V and serotype 
VII are identical, except for an additional glucose molecule linked to galactose in 
serotype V that was contributed by the cpsO gene (Cieslewicz et al, 2005). The 
genomic background (Section 3.4.1.5) was indistinguishable to that of serotype V (to 
MS VII，ID 113) and because cpsK, cpsB and cpsO genes were unique to serotype V 
and not in serotype VII，and cpsA was proposed as a transcription regulator, cpsB 
was tyroxine phosphatase (Chaffin et al.’ 2000; Cieslewicz et al, 2005), thus 
inactivation or loss of cpsO is the most probable factor to result in the switch. While 
another switched isolate (ID 116) shows distinct PFGE fingerprint and surface 
protein genes to other serotype V isolates, it may be a serotype V isolate switch to 
other serotype VII or vice versa. The capsular polysaccharide operon should be 
investigated to find out if there is partial recombination of the capsular genes. 
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Figure 4.1 Capsular polysaccharide forming unit of 9 GBS serotypes (Cieslewicz et 
a!., 2005) 
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4.1.2 Antibiotic susceptibility testing and resistance genes 
Worldwide, antibiotic resistance of GBS to tetracycline has varied from 84% to 
100% among GBS (Ko et al., 2001; Lee et al., 2000; Lin et al., 2000; Wemo et al, 
2003), with an exceptionally low rate (26%) in Japan (Matsubara et al, 2001). The 
tetracycline resistance rate in Hong Kong at 89.5%, is similar to New Zealand, 
Taiwan and the USA with high resistance rates. Similarly, the tet{M) gene was 
predominantly detected in 87.3% resistance isolates, equivalent to 85% in the 
previous report (Poyart et al., 2003). 4.5% of isolates did not harbour tet{M) nor 
tet{0). Other resistance determinants such as tet{T) and tet{L) that had been 
previously detected in GBS strains may be responsible for the tetracycline resistance 
(Poyart et al.，2003). A few isolates remained susceptible to tetracycline despite the 
.tetracycline resistance gene being present. The tetracycline resistance genes may be 
inactivated or not functional. 
Erythromycin resistance varied from 3% to 46%. Three percentages of resistance 
was found in Japan, while the highest, 46%, was observed in Taiwan. The 
erythromycin resistance rate in Hong Kong is 23.8% (Section 3.2.1). The rate is 
- lower than in Taiwan, but generally higher than Japan, New Zealand, Brazil and 
Spain (Aracil et al.’ 2002; d'Oliveira et al., 2003; Hsueh et al., 2001; Ko et al., 2001; 
Matsubara et al, 2001; Wemo et al., 2003). The major determinants for 
erythromycin resistance were erm{B), erm{TR) and meJ{A) and had been found in 
62%, 30.4% and 3.8% of resistant strains in Spain (Gonzalez et al., 2005). In Hong 
Kong, the erm(B) gene is predominant (43.2%), but the mef{A) gene (25%) is more 
frequent than erm(TR) (15.9%) gene (Section 3.2.2.2). The erm{B), erm{TR) and 
meJ{A) genes were not sufficient to explain all erythromycin resistance of GBS in 
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Hong Kong, 9 erythromycin resistant isolates carried none of erm(B), erm(TR) and 
meJ{A) gene. Other mechanisms may be present to account for this erythromycin 
resistance. 
Erythromycin resistance was distributed statistically significantly and frequently in 
colonizing strains (Section 3.2.1 and Table 3.6)，and this may be due to previous 
exposure to erythromycin in the population. This will have implication in particular 
in the use of erythromycin or clindamycin in chemoprophylaxis during labour or for 
treatment of GBS infection. Tet(M) and the integrase gene int-Tn were distributed 
statistically significantly in the invasive group, and may implicate the acquisition of 
tet{M) along with other genes transferred within the transposon. 
The distribution of antibiotic resistance among molecular serotypes illustrates that 
erm(TR) was present only in MS II isolates without accompanying erm(B) or mef[A) 
(Section 3.2.2.2 and Table 3.8). This indicated that the acquisition of erythromycin 
resistance gene is different between MS II cluster II-A and II-B and the other GBS 
strains (Section 3.4.1.2 and Appendix II: Dendrograms). While tet{0), erm{B), 
aphA3 and aad6 were predominant in MS lb isolates (see Appendix II: Dendrogram 
of MS lb), these genes clustered in Ib-A; they were probably transferred together in 
transposon such as Tnl545 carrying tet{M) with erythromycin and kanamycin 
resistance genes (Clewell et al., 1995). 
4.1.3 PFGE 
PFGE is a highly reproducible typing method with high discriminatory power. 
However, GBS isolates were unable to be typed by PFGE method (Bidet et al.’ 2003; 
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Gonzalez et al, 2005; Skjaervold et al,’ 2004), 9 GBS strains in this study were not 
digested by Smal and no fingerprint was generated (Section 3.3.1). The reason for 
the inability of Smal to digest GBS genomic DNA is unknown, a possible 
explanation may be the methylation of cystosine residues in the genome which 
prevented the recognition and cleavage by Smal (Butkus et al., 1987). 
The overall PFGE fingerprint patterns of Hong Kong GBS were heterogeneous, even 
in some clusters as characterized by the surface protein genes, mobile genetic 
elements and antibiotic resistance genes. All the surface protein genes, mobile 
genetic elements and antibiotic resistance genes were searched for Smal restriction 
sites by ChromasPro VI.22. Only the aphA3 (AF060241) gene harboured two Smal 
restriction sites and generated a 1585bp fragment. Therefore, the heterogeneity of 
PFGE patterns was independent of these 3 categories of genes and may be due to 
other unique sequences in these strains. 
4.1.4 Surface protein genes 
The major drawback of the genetic characterization of surface protein is the inability 
* to support its expression in the pathogenesis, but the presence of genes can be useful 
to distinguish the genetic variants between strains. 
The limitation of primers to detect C a protein repeating unit is the inability to 
examine the number of repeats in the C a protein gene, as previously the number of 
‘ repeat has directly been linked to the immunoevasion ability of C a protein 
(Gravekamp et al,, 1997). This problem may be solved by amplifying the whole 
region of the repeating, and the number of repeat can be determined directly by the 
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size of the amplicon. Another problem of the primers is the specificity. Sequence 
homologous to C a protein repeating unit is present in member of C a-like protein 
families, such as alpl gene. Isolates carried homology of C a protein repeating unit 
without C a protein gene or alpl gene, may carry protein such as Alpl or Alp4 
protein or even an unidentified protein. Moreover, members of C a-like protein 
families can be detected in single isolates (Dore et al., 2003). 
Among the distribution of surface protein genes between the 3 categories of 
specimen (Section 3.3.2)，rib protein gene "R" {p < 0.05，chi squared test) and C a 
protein gene were shown significantly distributed in wound/pus strains {p < 0.05 and 
p < 0.025)，"Aa" {p < 0.01, chi squared test) were shown to be significantly 
• distributed in invasive strains in Section 3.3.2. and the C a protein had been 
suggested to enhance pathogenicity (Nizet et al, 2000)，while C a protein was also 
shown to mediate internalization at the epithelial cell (Bolduc et al, 2002). The rib 
protein carried similar structure as C a protein and were gathered into C a-like 
protein family, therefore, they may have similar function and may explain why they 
were predominant in invasive strains. C a-like protein repeating unit was 
predominant in colonizing strains {p < 0.025), and it may be due to the number of 
repeat can alter the ability to evade host immunity (Gravekamp et al” 1997). 
4.1.5 Mobile genetic elements 
The limitation on the study of mobile genetic elements by PCR is the inability to 
determine the copy number and genetic loci of these elements in the genome. The 
copy number of each mobile genetic element and the loci varied between GBS 
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Strains (Dmitriev et al.’ 2003; Luan et al, 2003). The insertion of mobile genetic 
elements in other bacteria was shown to activate the expression of neighboring genes 
(Mahillon et al., 1998), and allow acquisition of genes (Mahillon, 1998). These 
provide significant information in identifying virulence genes and characterizing 
GBS. The presence of 187557, l^Sagl and ISSag2 were predominant in wound/pus 
strains (Section 3.3.3). The genes accompanied with ISI38J may enhance GBS 
infection in human, but further investigation of the gene linked or downstream of 
ISJ38J are necessary. 
4.1.6 Real-time PCR 
The aim of the development of a rapid detection and identification method to screen 
. G B S colonization, in particular to type invasive serotype III strains, in pregnant 
women at the time of labour, was achieved. Real-time PCR provides a sensitive 
method of detection with rapid results that can reduce the unnecessary usage of 
antibiotic in prophylaxis at time of labour (Reglier-Poupet et al., 2005). 
A real-time PCR based on the CAMP factor gene, cjh, has been tested on various 
* standard strains, clinical vaginal swabs and blood culture samples (Bergeron et al, 
2000; Davies et al, 2004b; Golden et al, 2004; Ke et al, 2000)，and now available 
as commercial kit IDI-Strep B (Infectio Diagnostic, Canada). Another real-time PCR 
reaction specific to GBS was based on the gene of Sip protein, a surface protein on 
GBS (Bergh et al, 2004). The major advantage of our PCR was the ability to detect 
‘ GBS and simultaneously identify serotype III. The probe designed in this experiment 
was able to differentiate serotype III subtype III-l and III-2 by Probe III from the 
other GBS serotypes. These two probes covered all major GBS serotypes, excluding 
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serotype VIII which is rare in most populations including Hong Kong. These 2 
subtypes of MS III were characterized with mobile genetic element IS1548 in III-l 
and GBSil in III-2. Because the serotype III strains harboured IS1548 was correlated 
to strain causing endocarditis in adult (Granlund et ai, 1998), while serotype III 
strain with GBSil was related to neonatal menginitis (Bidet et ai, 2003). Therefore, 
the probes designed in this project are able to identify the invasive clones of serotype 
III. Moreover, the subtypes III-l and 111-2，member of cluster III-A and III-B in 
Section 3.4.1.4，were found to be statistical significantly predominant in neonatal 
invasive strains in Hong Kong (Section 3.4.2). These two probes thus are useful in 
the identification of these serotypes in colonizing pregnant mothers. 
The detection limits on GBS culture using Probe III and Probe B were 1x10^ cfu/mL 
and 1.925x105 cfu/ml in vaginal flora spiked with GBS (Section 3.5.2). While in 
vaginal specimen spiked with GBS, the detection limits were tenfold lower, of 2x10^ 
cfu/ml for Probe III and 2.8x10^ cfu/ml for Probe B. This limitation may be due to 
the DNA extraction by the boiling method. The lowered efficiency of extraction and 
the possibility of inhibition of PCR by chemical from blood agar may reduce the 
detection limit from clinical specimens. 
The primers were unable to detect serotype VIII. Serotype VIII capsular 
polysaccharide operon sequence had not been identified at the time of the primer 
design, thus no information was available to determine its sequence diversity. The 
present serotype VIII capsular polysaccharide sequence shows that it is significantly 
varied from the other serotypes (Cieslewicz et al., 2005). This real-time PCR method 
required about 45 minutes for amplification and the result was only available after 
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the amplification in ABI Prism® 7900HT Sequence Detection System. This may be 
solved by optimization of the real-time PCR method on a faster thermal cycler, e.g. 
LightCycler™, to shorten the amplification period. The specificity of the primers and 
probes had been examined on lower vaginal swabs, but the sample size was too small. 
A larger evaluation in parallel with the culture method is needed to identify its 
specificity and sensitivity on vgainal tract/rectal specimen for GBS screening. 
4.2 Characterization of GBS in Hong Kong 
4.2.1 GBS in Hong Kong 
Surveillance on the serotypes of GBS is critical in understanding the epidemiology of 
GBS. The antibiotic resistance status and the serotype distribution are essential 
information for treatment and vaccine formulation. Epidemiology data also provide 
information to identify the virulent clone, which may relate to certain diseases 
include the endocarditis in adults and meningitis in neonates (Bidet et al., 2003; 
Granlund et al, 1998). 
The GBS serotypes predominant in Hong Kong are la, III and V (Section 3.1.1)，and 
the distribution is similar to that in the United States (Hickman et al, 1999)，Portugal 
(Figueira-Coelho et al.’ 2004) and Taiwan (Ko et al, 2001). The predominant 
serotypes differ to some Asian countries including Korea and Japan (Lachenauer et 
al.’ 1999; Lee et al, 2000) that reported predominant serotypes lb and VIII 
respectively. The most common five serotypes la, lb, II，III and V comprised 88% of 
GBS in Hong Kong. The potential of a pentavalent vaccine targeted on these five 
serotypes will provide good coverage of our prevalent serotypes. 
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The MS III strains are more likely cause invasive disease in Human. The MS III 
isolates were significantly found in invasive category (p < 0.001) (Section 3.1.4 and 
Table 3.4), particular the subtype III-4 which was distributed significantly in the 
invasive group. Most III-4 strains were isolated from invasive cases of adult, but no 
colonizing strain was found. Therefore, these strains are likely associated with adult 
invasive diseases. Moreover, the MS III-l and III-2 strains are significantly found in 
invasive cases of matemal/neonatal group (Section 3.4.2). Since three of four 
subtypes of MS III strains are correlated with invasive cases and can illustrate the 
association of MS III strains to invasive diseases in human. 
..Generally, 90% of Hong Kong GBS isolates are resistant to tetracycline, and most of 
them harboured the tet{}A) gene, which was a widely disseminated tetracycline 
resistance determinant in different species (Chopra et al, 2001). The integrase gene 
{int-Tn) of a transposon the ln916 families is frequently present among tetracycline 
resistance strains with tetQs/[) gene (Section 3.2.2.1), thus tetracycline resistance due 
to gene is possibly due to the acquisition of transposon of Tn976 family 
, (Poyart et al., 2003). Another tetracycline determinant, tet{0), has contributed 8.2% 
of the tetracycline resistance among the GBS. The tet{0) is almost mutually 
«i 
distributed with int-Tn in Hong Kong strains, thus it is less likely to be carried by the 
transposon of Tn916 families in Hong Kong GBS strains. It is interesting that about 
60% (18 / 29) of the tet{p) carrying strains also harboured the erythromycin 
resistance gene erm(B), aminoglycoside resistance gene aphA3 and aad6 genes. 
These genes may be carried by same transposable element in these GBS strains. 
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23.8% of the 370 GBS strains are resistant to erythromycin. The resistance rate is a 
little higher than France (18%) and Canada (17%) (Desjardins et al.’ 2004; Fitoussi 
et al.’ 2001)，but lower than the 33%-46% resistance reported in Taiwan (Hsueh et 
al., 2001; Ko et al, 2001). The erythromycin resistance mechanisms are similar to 
Spain and France that erwi(B) is the prevalent gene, but mej{K) is more frequent than 
erw(TR) in Hong Kong than in these two countries (Section 3.2.2.2) (Fitoussi et al, 
2001; Gonzalez et al.’ 2005). 
The relationship of the PFGE, surface protein genes, mobile genetic elements and 
resistance genes are grouped into clusters within each molecular serotype. In MS la, 
4 clusters were obtained; each with their unique surface protein genes and mobile 
genetic elements (Section 3.4.1.1). The invasive GBS did not aggregate in any 
particular cluster. A predominance of strains, cluster la-A, of MS la, especially was 
associated with maternal and neonatal colonizing, and relatively uncommon for 
invasive disease. Because C a and a-like protein are considered to enhance 
pathogenicity (Bolduc et al., 2002; Nagano et al, 2002; Puopolo et al.’ 2003), and 
isolates deficient in C a protein is more readily cleared than wild type by immune 
cells (Li et al, 1997)，therefore, C a-like protein family are expressed on the surfaces 
of GBS (Lindahl et al, 2005). Interestingly, 4 invasive strains in cluster la-B did not 
harbour these genes, and it is likely that other mechanism may play a role to achieve 
the immunevasion. The mobile genetic elements, ISSagl and lSSag2, are commonly 
found in human GBS (Franken et al.’ 2001; Franken et al, 2004). These enable 
, lineage classification, and indicate these strains may differ in its derivation from 
other MS la strains. 
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Isolates in MS lb were generally much more homogeneous, and were characterized 
by the presence of C a and (3 proteins, IS86J’ IS/557, ISSag] and lSSag2 (Section 
3.4.1.2). Two clusters were identified by the antibiotic resistance determinants, tet(M) 
or tet(0). No integrase gene int-Tn was detected in tet{0) harbouring cluster Ib-A. 
Cluster Ib-B carried the tetQA) gene. The teti^) gene is likely to have been acquired 
by horizontal transfer (Rice, 1998). While, the tet{0) plus erm(B) are frequently 
found in bovine isolates (Duarte et al., 2005)，these strains may be related to that of 
the bovine source. Clusters Ib-A and Ib-B may thus be derived from different 
serotype lb clones. 
The 2 major clusters, II-A and II-B, differ in their PFGE and the surface protein 
genes, mobile genetic elements and antibiotic resistance genes (Section 3.4.1.3). 
There is no predominance of invasive isolates in these clusters. Cluster II-B was 
characterized by the lSSa4 and erm{TK) genes, which were only found in this cluster 
among 370 GBS isolates, except for 1 isolate in MS lb carrying an lSSa4 gene. 
The MS III strains in Hong Kong are consistent with the previous description that 
1875^5 and GBSil are exclusively distributed (Granlund et al, 2001). The presence 
or absence of these two mobile genetic elements, could differentiate the main groups 
of GBS serotype III; as in clusters III-A/D/E, with only IS1548 but not GBSil, 
cluster B that contain GBSil and cluster C that harboured neither IS1548 nor GBSil. 
A total of 6 clusters were identified in MS III strains (Section 3.4.1.4 and Appendix 
III). The cluster III-A is the 1875^5 harbouring isolates and belongs to the MS III-l 
(Section 3.4.1.4)，and likely to be equivalent to the restriction digestion pattern (RDP) 
type III-2 and sequence type sequence type (ST) 19 by MLST through the presence 
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of ISl548 (Jones et al, 2003). Similarly, cluster III-B, MS III-2 isolates, harbour the 
GBSil element and are likely the RDP type III-3 and ST 17’ named as the neonatal 
invasive clone (Bohnsack et al, 2002; Granlund et al., 1998; Jones et al.’ 2003). 
However, this would await further confirmation by MLST of the representatives of 
these clusters. 
In this study, a cluster of MS III isolates that did not carry ISI548 and GBSil�were 
isolated from adult invasive cases (cluster III-C) indicating that virulence clones of 
GBS serotype III may not necessary harbour these mobile genetic elements (Section 
3.4.1.4 and Figure 3.14). The isolates were assigned to MS III-4 by DNA sequencing 
(Section 3.1.3) and carried distinct PFGE fingerprints (Section 3.3.1). Most of these 
strains were isolated from year 1998, and may be linked to an GBS outbreak in adult 
meningitis in Asia, with cases described from Hong Kong and Singapore (Chan et al., 
2002; Wilder-Smith et al., 2000). Moreover, it is still present in the GBS population 
in year 2003. This strain may be a new virulent clone different from the previously 
reported RDP type III-3 (Bohnsack et al., 2001). 
Cluster III-D is characterized with complex PFGE fingerprints, and up to 20 Smal 
digested fragments were observed. The incorporation of numerous Smal restriction 
sites is unusual. Because the GC content of GBS strains is around 35% (Glaser et al, 
2002; Tettelin et al.’ 2002) and the numbers of Smal restriction site in other strains 
are not as many as this cluster. It is possible these strain have acquired DNA 
fragment with additional Smal restriction sites. 
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The characteristic of MS V in Hong Kong is also interesting. Among MS V isolates, 
three clusters were identified (Section 3.4.1.5). The cluster V-A harboured alp3 gene 
and appeared to be more associated with invasiveness than cluster V-B and V-C. 
11/16 invasive cases were found in cluster V-A, however, statistical significant was 
not reached. Cluster V-B has unique features from cluster V-A and V-C. Cluster V-B 
isolates harbour both GBSil and \S1548 gene, which were exclusively present in MS 
III. The mutual exclusion of GBSil and IS1548 was only described in serotype III. 
Since there are 3 insertion sites for GBSil (Luan et al., 2003)，it may be found in 
other location and not compete with 1875^5 insertion at downstream of scpB gene. 
An additional phenotypic observation of cluster V-B is that it does not express beta-
haemolysin on horse blood agar in all these isolates. This feature could significantly 
affect routine isolation and identification of the GBS in a diagnostic microbiology 
laboratory. The target regions for inactivating beta-haemolytic activity included 
acpC, cy/A, cylB and cylE genes.棚a4 and IS7557-variant have been described to 
insert in cylB gene (Pritzlaff e/‘ al, 2001; Spellerberg et ai, 1999; Spellerberg, 2000), 
thus leading to the absence of haemolysis. Since \SSa4 was not detected in this 
cluster, it will not explain this phenomenon. It may be possible to elucidate this loss 
of haemolysin production through targeting these gene loci. 
The pathogenic mechanisms in these isolates should be investigated. Although host 
factors and the host interaction also play a role in invasive disease, the genetic 
differences between invasive and non-invasive strain may also provide information 
to understand the pathogenic determinants and mechanism of GBS disease. 
Subjective hybridization has been used successfully to identify virulence genes 
among GBS serotype III strains (Adderson et al, 2003). This method can subtract 
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genes with similar sequence between tested strains and isolate those unique 
sequences (Lisitsyn et al, 1993). Virulence factors within invasive strains in cluster 
la-A, V-B and invasive cluster III-C may be examined to identify virulence factors 
that enhance the pathogenicity of the sporadic invasive isolates clustered within the 
colonizing strains. 
4.2.2 GBS from Australia and Korea 
Our Hong Kong isolates were compared to the database of GBS from Australia and 
Korea (Dr Fanrong Kong, Professor Gwendolyn L. Gilbert, ICPMR, Westmead, New 
South Wales, Australia, unpublished data). Several clusters/strains including cluster 
Ib-A, III-C, V-B and MS IV strains were not found in Australia and Korea (Section 
• 3.4.3). Whilst strains of cluster la-B, la-C, la-D are dominant among Australian and 
Korean strains, this may indicate GBS strains in Hong Kong have unique features 
that may not be found in other countries, especially the adult invasive strains of 
cluster III-C. For a more detailed comparison, sequence types of MLST of these 
strains should also be examined to identify its relatedness to GBS population in other 
countries. 
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4.3 Future research 
A worldwide database of the population structure of GBS strains is now available on 
the MLST database (http://sagalactiae.mlst.net). Thus, representatives of our 
prevalent clusters of GBS in Hong Kong should be examined for comparison. In 
particular the major clusters of MS III subtypes should also be further examined for 
the pathogenic mechanism(s) should be resolved, particularly the strains of MS III-4 
in Hong Kong which were unique and confined to Hong Kong,. Moreover, its 
pathogenic mechanism(s) and frequency in distribution in the GBS population should 
be investigated. Finally, the evaluation of the real-time PCR identification in clinical 
practice should be explored. 
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4.4 Conclusions 
The serotype III is the commonest strains in Hong Kong and followed by serotypes 
la and V. The molecular serotype III is prevalent in maternal and neonatal strains and 
associated with invasive disease {p < 0.001)，particular MS III-l and III-2 strains {p < 
0.05，p < 0.001). While, the MS III-4 is a unique invasive associated with adult 
invasive diseases {p < 0.001) in Hong Kong and present since 1995. The antibiotic 
susceptibility test indicates that all isolates in Hong Kong are susceptible to penicillin. 
Eighty-nine point five percentages of GBS strains are resistant to tetracycline, 86.7% 
of tetracycline resistant strains harboured tet{}A) gene and 8.2% has tet{0) gene 
respectively. Twenty-three point eight percentages of GBS strains are resistant to 
erythromycin, erm(&) is prevalent in 43.2% strains and meJ{A) is prevalent in 25% of 
resistance strains. A cluster of MS V isolates was found didn't show beta-haemolysis 
on horse blood agar and may pose a difficulty in the identification in a diagnostic 
laboratory. A real-time PCR is established to identify GBS and specifically targets 
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Appendix I: Materials and Reagents 
A. Materials 
1. Identification and storage 
Material/Reagent Manufacturer Catalog No. 
Bacitracin disk (0.05U) Oxoid, UK DD0002 
Streptex (latex Murex, UK ZL50/9E05-01 
agglutination test) 
Ninhydrin salt Sigma, USA 
Bile Aesculin Agar 
Glycerol broth 
Blood agar 
2. Antibiotic susceptibility test 
Material/Reagent Manufacturer Catalog No. 
Columbia blood agar 
Mueller Hinton broth 
powder 
Horse blood 
Brain Heart Infusion broth 
powder 
Ciprofloxacin Bayer, Elberfed 303477A 
Gatifloxacin BMS 20658401 
Levofloxacin Daiichi Pharmaceutical Co 
Ltd, Japan 
Moxifloxacin Bayer, Elberfed 502714 
Lincomycin Sigma, USA L-6004 
Erythromycin Sigma, USA E-6376 
Tetracycline Sigma, USA T-3383 
Penicillin Sigma, USA D-3032 
Chloramphenicol Sigma, USA C-3078 
Linezolid ZYVOX, USA 00095-140-07 
Amplicin Sigma, USA A-9518 
ATCC 49619 
O.lNNaOH 
95% Ethanol , CSR, Australia lOOHG 
DMSO BDH, England Prod 10323 
Neutral red SERVA, USA 30350 




3. Pulsed-field gel electrophoresis 
Material/Reagent Manufacturer Catalog No. 
Blood agar 
Sea Plaque GTG agarose Cambrex, USA 50071 
(Low-melting agarose) 
Seakem LE agarose Cambrex, USA 50004 
Pulsed Field Certified BioRad, USA 162-0138 
Agarose 
CHEF Mapper XA BioRad, USA 170-3670 
Cooling Module BioRad, USA 
Bionumerics v3.50 Applied Maths, Belgium 
TE Buffer land 2 
ES Buffer 
lOX TBE Buffer 
Gram positive lysis buffer 
Lysozyme Sigma, USA L-6876 
Proteinase K USB, UK 76230Y 
Mutanolysin Sigma, USA M9901 
Smal Amersham, USA E1085W 
lOx T Buffer Amersham, USA 
0.1% BSA Amersham, USA 入-phage PFGE DNA Amersham, USA 27-4530 
marker 
Ethidium bromide Sigma, USA E-8751 
ImageMaster imaging Pharmacia Biotech, Israel 80-6247-01 
system 
Water bath 
McFarland Standard bioMerieux, France REF70900 
4. Serotyping 
Material/Reagent Manufacturer Catalog No. 
GBS antigen extraction kit Denka Seiken，Japan 240040 
GBS la, lb, II-V antisera Denka Seiken, Japan 200471 
GBS VI antiserum Denka Seiken, Japan 293350 
GBS VII antiserum Denka Seiken, Japan 293374 
GBS VIII antiseru Denka Seiken, Japan 293367 
Phosphate buffered saline 
Todd Hewitt broth 




5. Molecular Characterization 
Material/Reagent Manufacturer Catalog No. 
Primers Invitrogen, USA 
Taq polymerase Amersham, USA 27-0799-61 
1 Ox PGR buffer Amersham, USA 
dNTP mix Amersham, USA 
Digestion buffer 
TE buffer 3 
Heat block 
GeneAmp PGR System Applied Biosystem, USA 
9700 
Seakem LE agarose Cambrex, USA 50004 
1 OObase-pair DNA marker Promega, USA G6951 
6X Loading Dye 
ImageMaster imaging Pharmacia Biotech, Israel 80-6247-01 
system 
Ethidium bromide Sigma, USA E-8751 
Gel electrophoresis tank BioRad, USA 
6. Real-time PGR 
Material/Reagent Manufacturer Catalog No. 
TaqMan® Probe Applied Biosystem, USA 4332077 
2x TaqMan® Universal Applied Biosystem, USA 4304437 
PGR Master Mix 
Blood agar 
Todd Hewitt broth with 
gentamicin and nalidixic 
acid 
Digestion buffer 
7900HT Real-time PGR Applied Biosystem, USA 4329003 
“ system 
Optical 96-Well Fast Applied Biosystem, USA 4346906 
Thermal Cycling Plate 
ABI P R I S M tm Optical Applied Biosystem, USA 4323032 
Caps (8 caps/strip) 
TOPO TA cloning kit Invitrogen, USA K4550-01 





Chemical Name Manufacturer Catalog No. 
Boric acid Merck, Germany K24056415 
Brij 58 Sigma, USA P5884 
CaCl2 BDH, England Prod 27588 
EDTA Sigma, USA ED2SS 
Glycerin BDH, England Prod 101186M 
KCl Sigma, USA P4504 
MgCh Merck 728 Al 89133 
NaCl Amersco, Ohio X190-5KG 
Na2HP04 BDH, England Prod 30158 
NaH2P04 BDH, England Prod 10245 
N-laury-sarcosine Sigma, USA L9150 
Ninhydrin Sigma, USA N4876 
Sodium deoxycholate BDH, England Prod 43035 
Sodium Hippurate Sigma, USA H9380 
Tris-Base Sigma, USA T-8524 
8. Broth/Agar powder 
- N a m e " Manufacturer Catalog No. 
Brain Heart Infusion powder Oxoid, UK CM0225 
Bile aesculin agar powder Oxoid, UK CM0888 
Columbia blood agar base powder Oxoid, UK CM0331 
Lab-Lemco powder Oxoid, UK LP0029 
Mueller-Hinton broth powder Oxoid, UK CM0405 
Mueller-Hinton agar powder Oxoid, UK CM0337 
Todd Hewitt broth powder Oxoid, UK CMO189 
Tryptone Powder Oxoid, UK LP0042 
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B. Buffer and Media 
1. 1% Sodium hippurate broth 
Hippurate acid-Sodium salt lOg，Distilled water IL 
2. lOX TBE buffer 
445mM Tris-Base，lOmM EDTA, 445mM Boric Acid 
3. Blood agar 
39g Columbia Blood Agar Base, 50mL Horse Blood, 1 Litre Distilled Water 
4. Bile aesculin agar 
44.5g Bile Aesculin Agar Powder, 1 Litre Distilled Water 
5. Brain Heart Infusion Broth 
Brain Heart Infusion powder 74g, Distilled Water 1 Litre 
6. Digestion buffer 
lOmM Tris-HCl, 0.45% Triton X-100, 0.45% Tween 20, pH 8.0 
7. DNA loading dye 100ml 
Bromophenol Blue 0.025%, Glycerol 30mL, Distilled Water 70mL 
8. ES buffer 
EDTA 0.5M (dissolved in lOM NaOH), N-laury-sarcosine 1%, pH 9.0, 1 Litre 
Distilled Water 
9. Gram posiitve lysis buffer 
6mM Tris-Base, lOOmM EDTA, IM NaCl, 0.5% w/v Brij 58, 0.5% w/v Sodium 
Deoxycholate, 0.5% w/v N-Lauroyl Sarcosine, ImM MgCh, PH 7.5 
10. Glycerol broth (Without salt) 
2g Lab-Lemco Powder, 2g Tiyptone, 20ml Glycerin, 180mL distilled water 
• 11. Mueller-Hinton Broth 5L 
21g Mueller-Hinton Broth, 1 Litre Distilled Water 
12. Mueller-Hinton Agar 8L 
38g Mueller-Hinton Agar, 1 Litre Distilled Water 
13. Ninhydrin reagent 
Ninhydrin 35g, Acetone butanol (1:1) by volume IL 
14. Normal saline ( 7 % ) ‘ 
Sodium Chloride 70g，Distilled water 1 Litre 
15. Phosphate-buffered Saline 
137mM NaCl, 2.7mM KCl, lOmM NazHPCU’ .5mM NH2PO4, 0.9mM CaCh, 
0.5mM MgClz, 1 Litre Distilled Water, pH 7.2 
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16. Todd Hewitt broth with gentamycin and nalidixic acid 
36.4g Todd Hewitt broth powder, Sp-g/mL gentamycin, 15|ig/mL nalidixic acid 
17. Tris-EDTA buffer 1 (TE 1) 
lOOmM Tris-Base, lOOmM EDTA, pH 7.6 
18. Tris-EDTA buffer 2 (TE 2) 
lOmM Tris-Base, ImM EDTA, pH 7.6 
19. Tris-EDTA buffer 3 (TE 3) 
5mM Tris-Base, 0.5mM EDTA, pH 7.6 
20. Todd-Hewitt broth 
36.4g Todd Hewitt Broth, 1 Litre Distilled Water 
C. Preparation of Mueller Hinton broth 
supplemented with lysed horse blood 
Horse blood was thoroughly lysed by freezing and thawing between - 2 0 � C and room 
temperature several times. Equal volume of sterile distilled water was mixed with 
blood aseptically. Any debris was removed by centrifUgation at 12，000g for 20 
minutes. After that, supernatant was descanted. MH broth supplement with 5% lysed 
horse blood (MH + LHB) was made by mixing 50 rtiL lysed horse blood with 450ml 
MH broth to a final 5% lysed horse blood concentration. The MH + LHB broth was 
freshly prepared before the antibiotic dilution preparation. 
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